Page last updated: 2024-11-11

gambogic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

gambogic acid: RN given refers to (1R-(1alpha,1(Z),3abeta,5alpha,11beta,14aS*))-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9852185
CHEMBL ID555017
SCHEMBL ID16160279
MeSH IDM0149407

Synonyms (39)

Synonym
guttic acid
.beta.-guttiferin
cambogic acid
1,5-methano-1h,3h,11h-furo(3,4-g)pyrano(3,2-b)xanthene-1-crotonic acid, 3a,4,5,7-tetrahydro-8-hydroxy-alpha,3,3,11-tetramethyl-13-(3-methyl-2-butenyl)-11-(4-methyl-3-pentenyl)-7,15-dioxo-, (z)-
b''-guttiferin
gambogic acid
beta-guttiferin
CHEMBL555017
(-)-gambogic acid
r-gambogic acid
bdbm50366237
8n585k83u2 ,
unii-8n585k83u2
|a-guttiferin
guttatic acid
beta-guttiferrin
S2448
BP-22199
CS-1456
HY-N0087
GEZHEQNLKAOMCA-RRZNCOCZSA-N
(2z)-2-methyl-4-((1r,3as,5s,11r,14as)-3a,4,5,7-tetrahydro-8-hydroxy-3,3,11-trimethyl-13-(3-methyl-2-buten-1-yl)-11-(4-methyl-3-penten-1-yl)-7,15-dioxo-1,5-methano-1h,3h,11h-furo(3,4-g)pyrano(3,2-b)xanthen-1-yl)-2-butenoic acid
gambogic acid [mi]
2-butenoic acid, 2-methyl-4-((1r,3as,5s,11r,14as)-3a,4,5,7-tetrahydro-8-hydroxy-3,3,11-trimethyl-13-(3-methyl-2-buten-1-yl)-11-(4-methyl-3-penten-1-yl)-7,15-dioxo-1,5-methano-1h,3h,11h-furo(3,4-g)pyrano(3,2-b)xanthen-1-yl)-, (2z)-
AC-34804
gambogic-acid
AKOS024463359
SCHEMBL16160279
(z)-4-((1s,3ar,5s,11r,14as)-8-hydroxy-2,2,11-trimethyl-13-(3-methylbut-2-en-1-yl)-11-(4-methylpent-3-en-1-yl)-4,7-dioxo-1,2,5,7-tetrahydro-11h-1,5-methanofuro[3,2-g]pyrano[3,2-b]xanthen-3a(4h)-yl)-2-methylbut-2-enoic acid
gambogic acid, >=95% (hplc), powder
alpha-gambogic acid
|a-guttilactone
BCP21539
Q5519727
mfcd16878985
CCG-270284
H10129
(z)-4-[(1s,2s,8r,17s,19r)-12-hydroxy-8,21,21-trimethyl-5-(3-methylbut-2-enyl)-8-(4-methylpent-3-enyl)-14,18-dioxo-3,7,20-trioxahexacyclo[15.4.1.02,15.02,19.04,13.06,11]docosa-4(13),5,9,11,15-pentaen-19-yl]-2-methylbut-2-enoic acid
DTXSID101029723

Research Excerpts

Overview

Gambogic acid (1) is a cytotoxic caged xanthone derived from the resin of Garcinia hanburyi. It has antiinflammatory, antioxidant, and neuroprotective properties and acts as a chemopreventive agent.

ExcerptReferenceRelevance
"Gambogic acid (GA) is a promising natural anticancer candidate. "( Metabolism of gambogic acid in rats: a rare intestinal metabolic pathway responsible for its final disposition.
Ding, L; Hu, L; Jin, S; Qian, W; Sun, X; Wang, Z; Xiao, W; Yang, J, 2011
)
2.17
"Gambogic acid (1) is a cytotoxic caged xanthone derived from the resin of Garcinia hanburyi. "( Gambogic acid deactivates cytosolic and mitochondrial thioredoxins by covalent binding to the functional domain.
Ding, L; Guo, Q; Jin, S; Li, C; Yang, J; You, Q, 2012
)
3.26
"Gambogic acid (GA) is a natural product with a wide range of pharmacological properties. "( Research Progress in the Field of Gambogic Acid and Its Derivatives as Antineoplastic Drugs.
Li, J; Li, M; Lv, S; Su, F; Wei, Y; Zhang, H; Zhao, Y; Zhu, M, 2022
)
2.44
"Gambogic acid (GA) is a naturally occurring and potent anticancer agent that destroys tumor cells through multiple mechanisms."( Nanoemulsion Co-Loaded with XIAP siRNA and Gambogic Acid for Inhalation Therapy of Lung Cancer.
Bai, L; Guo, Y; Kuang, M; Liu, X; Luo, Y; Sun, M; Wang, B; Wang, C; Xie, J; Xu, M; Zhang, L, 2022
)
1.71
"Gambogic acid is a potent antineoplastic agent without the drawback of bone marrow suppression."( Lactoferrin-Modified Gambogic Acid Liposomes for Colorectal Cancer Treatment.
Chen, G; Huang, Y; Li, Q; Muhitdinov, B; Ou, A; Qu, J; Tang, X; Wang, R; Zhang, J; Zheng, C, 2023
)
1.95
"Gambogic acid (GA) is a natural xanthonoid secreted by "( Gambogic Acid Inhibits Gastric Cancer Cell Proliferation through Necroptosis.
Chen, M; Wang, S; Wang, Y; Zhang, L; Zhu, H, 2023
)
3.8
"Gambogic acid (GA) is a natural anti-tumor drug whose application is restricted by its poor aqueous solubility and inefficient bioavailability. "( CD44 targeted redox-triggered self-assembly with magnetic enhanced EPR effects for effective amplification of gambogic acid to treat triple-negative breast cancer.
Feng, F; Han, L; Liu, F; Liu, W; Luo, R; Qu, W; Sang, M; Xue, J; Zhang, K; Zheng, F, 2019
)
2.17
"Gambogic acid (GA) is a natural compound with a polyprenylated xanthone structure that has antiinflammatory, antioxidant, and neuroprotective properties and acts as a chemopreventive agent. "( Gambogic Acid Affects Ribosomal Occurrence in Glioma Cells by Downregulating the Phosphoinositide Kinase-3/Protein Kinase B/Mammalian Target of Rapamycin Signaling Pathway.
Jiang, S; Ling, Y; Luo, G; Luo, H; Zhang, X; Zhang, Y, 2020
)
3.44
"Gambogic acid (GA) is a natural compound with a polyprenylated xanthone structure and possesses remarkable antitumor activity in a variety of cancer cells."( Critical role of miR-26a-5p/Wnt5a signaling in gambogic acid-induced inhibition of gastric cancer.
Cao, G; Liang, L; Zhang, Z, 2021
)
1.6
"Gambogic acid (GA) is a xanthone structure extracted from the dry, brownish gamboge resin secreted from the Garcinia hanburyi tree in Southeast Asia and has inherent anti-cancer properties."( Therapeutic potential of gambogic acid, a caged xanthone, to target cancer.
Arfuso, F; Banik, K; Bordoloi, D; Harsha, C; Kumar, AP; Kunnumakkara, AB; Lalduhsaki Sailo, B; Leong, HC; Mishra, S; Sethi, G; Wang, L, 2018
)
1.51
"Gambogic acid (GA) is a natural antitumor drug candidate with advantages of broad-spectrum activity, low toxicity and multiple mechanisms. "( Improved druggability of gambogic acid using core-shell nanoparticles.
Duan, B; Feng, F; Han, L; Hu, L; Huang, X; Jiang, P; Liu, B; Liu, F; Liu, J; Liu, W; Ma, C; Qiao, Z; Qu, W; Sang, M; Wang, X, 2019
)
2.26
"Gambogic acid is a pure active compound isolated from the traditional Chinese medicinal plant gamboge (Garcinia morella Desv.). "( An open-labeled, randomized, multicenter phase IIa study of gambogic acid injection for advanced malignant tumors.
Chi, Y; Cui, CX; Hu, JF; Wang, JW; Wang, YG; Wang, ZZ; Xiao, W; Xie, GR; Xiong, FX; Yang, L; Yu, H; Zhan, XK, 2013
)
2.07
"Gambogic acid (GA), which is a Garcinia natural product with a unique caged xanthone scaffold, inhibits potent antitumor activity both in vitro and in vivo."( [Progress in research of the structural optimization of natural product-like Garcinia caged xanthones].
Sun, HP; Wang, YY; Yang, YR; You, QD; Zhang, XJ, 2014
)
1.12
"Gambogic acid (GA) is an anticancer agent in phase ‖b clinical trial in China but its mechanism of action has not been fully clarified. "( Proteomic and bioinformatic analyses of possible target-related proteins of gambogic acid in human breast carcinoma MDA-MB-231 cells.
Cui, YJ; Feng, LX; Guo, DA; Jiang, BH; Li, D; Liu, M; Liu, X; Qu, XB; Song, XY; Wu, WY; Yang, M; Yue, QX, 2015
)
2.09
"Gambogic acid (GA) is an anticancer agent in phase IIb clinical trial in China. "( Proteomic Analysis Revealed the Important Role of Vimentin in Human Cervical Carcinoma HeLa Cells Treated With Gambogic Acid.
Cao, B; Feng, L; Guo, D; Jiang, B; Liu, M; Liu, X; Wu, W; Yang, M; Yue, Q; Zhang, D, 2016
)
2.09
"Gambogic acid (GA) is a natural compound derived from brownish gamboge resin that shows a range of bioactivity, such as antitumor and antimicrobial properties. "( Gambogic acid induces apoptosis and sensitizes TRAIL-mediated apoptosis through downregulation of cFLIPL in renal carcinoma Caki cells.
Jang, JH; Kim, EA; Kim, JY; Lee, TJ; Sung, EG, 2016
)
3.32
"Gambogic acid (GA) is a naturally derived potent anticancer agent with extremely poor aqueous solubility. "( Tumor neovasculature-targeted cationic PEGylated liposomes of gambogic acid for the treatment of triple-negative breast cancer.
Doddapaneni, R; Owaid, IH; Patel, K; Singh, M, 2016
)
2.12
"Gambogic acid which is an effective antitumor ingredient with very short half-life, was used as a model drug to prepare long-circulating liposome in this research."( Novel Long-Circulating Liposomes Consisting of PEG Modified β-Sitosterol for Gambogic Acid Delivery.
Tang, X; Yu, F, 2016
)
1.38
"Gambogic acid (GA) is a promising chemotherapeutic compound that could increase the chemotherapeutic effectiveness of CDDP in human OS cells by inducing cell cycle arrest and promoting apoptosis."( Hypoxia-induced resistance to cisplatin-mediated apoptosis in osteosarcoma cells is reversed by gambogic acid independently of HIF-1α.
Xia, SQ; Xu, GP; Yan, JL; You, CC; Zhang, ZP; Zhao, W; Zhuang, JP, 2016
)
1.37
"Gambogic acid (GA) is a potential anti-cancer agent with poor water-solubility, whereas heparin has anti-angiogenesis effects with good hydrophilicity. "( Gambogic acid grafted low molecular weight heparin micelles for targeted treatment in a hepatocellular carcinoma model with an enhanced anti-angiogenesis effect.
He, L; Peng, D; Yan, X; Yang, Y; Yin, D, 2017
)
3.34
"Gambogic acid (GA) is a natural product with potent apoptotic activity. "( Gambogic acid mediates apoptosis as a p53 inducer through down-regulation of mdm2 in wild-type p53-expressing cancer cells.
Gu, H; Guo, Q; Ling, H; Liu, W; Lu, N; Mu, R; Qi, Q; Rao, S; Ren, FL; Wang, J; Wang, X; Yang, Y; You, Q; Zhao, J, 2008
)
3.23
"GA (gambogic acid) is a polyprenylated xanthone abundant in the resin of Garcinia morella and Garcinia hanburyi with a long history of use as a complementary and alternative medicine. "( Gambogic acid covalently modifies IkappaB kinase-beta subunit to mediate suppression of lipopolysaccharide-induced activation of NF-kappaB in macrophages.
Arner, RJ; Gandhi, U; Kalantari, P; Narayan, V; Palempalli, UD; Prabhu, KS; Ravindran, A; Vunta, H, 2009
)
2.35
"Gambogic acid (GA) is a major active ingredient of gamboge, a widely used traditional Chinese medicine that has been reported to be a potent cytotoxic agent against some malignant tumors. "( The NF-kappa B inhibitor, celastrol, could enhance the anti-cancer effect of gambogic acid on oral squamous cell carcinoma.
Chen, W; Duan, W; He, D; Xu, Q; Yan, M; Ye, D; Zhang, P; Zhang, Z; Zhong, L; Zhou, X, 2009
)
2.02
"Gambogic acid (GB) is an important anti-cancer drug candidate, but the target protein by which it exerts its anti-cancer effects has not been identified. "( Gambogic acid inhibits Hsp90 and deregulates TNF-α/NF-κB in HeLa cells.
Chen, J; Guo, Q; Song, S; Sun, Y; Yi, Y; Zhang, L; Zheng, Z, 2010
)
3.25
"Gambogic acid is a xanthone derived from the resin of the Chinese plant Garciania hanburyi, with potent anti-metastasis activity on highly metastatic cells."( Gambogic acid inhibits tumor cell adhesion by suppressing integrin β1 and membrane lipid rafts-associated integrin signaling pathway.
Chen, Y; Guo, Q; Li, C; Li, F; Li, Z; Ling, Y; Lu, N; Qi, Q; Qin, Y; You, Q; Zhang, H, 2011
)
2.53
"Gambogic acid (GA) is a caged xanthone that is derived from Garcinia hanburyi and functions as a strong apoptotic inducer in many types of cancer cells. "( Gambogic acid is a novel anti-cancer agent that inhibits cell proliferation, angiogenesis and metastasis.
Chen, W; Wang, X, 2012
)
3.26
"Gambogic acid (GA) is a naturally derived novel anticancer agent, but poor solubility and toxic side effects limit its use."( Poloxamer 407/TPGS mixed micelles for delivery of gambogic acid to breast and multidrug-resistant cancer.
Hussain, MD; Saxena, V, 2012
)
1.35
"Gambogic acid (GA) is a natural compound derived from Chinese herbs that has been approved by the Chinese Food and Drug Administration for clinical trials in cancer patients; however, its molecular targets have not been thoroughly studied. "( Gambogic acid is a tissue-specific proteasome inhibitor in vitro and in vivo.
Dong, X; Dou, QP; Guan, L; Guo, H; Huang, H; Jiang, L; Li, B; Li, S; Li, X; Liao, S; Liu, C; Liu, J; Liu, N; Liu, S; Liu, Y; Lu, X; Ma, N; Shi, X; Song, W; Tan, H; Wang, S; Wang, X; Wen, G; Yang, C; Zhang, C; Zhao, C; Zhao, K; Zhou, P, 2013
)
3.28

Effects

Gambogic acid (GA) has a significant anticancer effect on a wide variety of solid tumors. GA has a marked anti-tumor effect for gastric and colorectal cancers.

Gambogic acid (GA) has been proven to be a potent chemotherapeutic agent for the treatment of lung cancer in clinical trials. The compound has been shown to inhibit cancer cell proliferation, induce apoptosis, and enhance reactive oxygen species accumulation.

ExcerptReferenceRelevance
"Gambogic acid (GA) has a significant anticancer effect on a wide variety of solid tumors. "( Synergistic effect of magnetic nanoparticles of Fe(3)O(4) with gambogic acid on apoptosis of K562 leukemia cells.
Chen, B; Chen, W; Cheng, J; Ding, J; Gao, C; Gao, F; Li, G; Li, X; Liang, Y; Liu, L; Shao, Z; Sun, X; Wang, X; Wu, W; Xia, G; Xu, W, 2009
)
2.04
"Gambogic acid has a marked anti-tumor effect for gastric and colorectal cancers in vitro and in vivo. "( Synergistic anti-proliferative effects of gambogic acid with docetaxel in gastrointestinal cancer cell lines.
Chen, J; Liu, B; Qian, X; Wang, T; Wei, J; Xie, L; Yu, L; Zou, Z, 2012
)
2.09
"Gambogic acid (GA) has been reported to be a potent apoptosis inducer. "( Studies on chemical modification and biology of a natural product, gambogic acid (II): Synthesis and bioevaluation of gambogellic acid and its derivatives from gambogic acid as antitumor agents.
Guo, Q; Li, C; Ma, J; Wang, F; Wang, J; You, Q; Zhao, L, 2010
)
2.04
"Gambogic acid (GA) has been observed to effectively impede the progression of numerous types of cancers. "( MiR-1275 Targeting SPARC Promotes Gambogic Acid-Induced Inhibition of Gastric Cancer.
Cai, A; He, Y; Lv, J; Xia, P; Zhou, X, 2023
)
2.63
"Gambogic acid has been reported to have anti-inflammatory effect."( Gambogic acid ameliorates high glucose- and palmitic acid-induced inflammatory response in ARPE-19 cells via activating Nrf2 signaling pathway: ex vivo.
Chen, J; Chen, L; Li, L; Zhang, J; Zhou, Y, 2021
)
2.79
"Gambogic acid (GA) has been reported to induce apoptosis in cholangiocarcinoma (CCA) cell lines. "( Gambogic Acid Inhibits Wnt/β-catenin Signaling and Induces ER Stress-Mediated Apoptosis in Human Cholangiocarcinoma.
Anantachoke, N; Bhukhai, K; Chairoungdua, A; Janpipatkul, K; Reabroi, S; Reutrakul, V; Suksen, K; Thongon, N, 2021
)
3.51
"Gambogic acid (GA) has been shown to inhibit cancer cell proliferation, induce apoptosis, and enhance reactive oxygen species accumulation. "( Gambogic acid improves non-small cell lung cancer progression by inhibition of mTOR signaling pathway.
Hu, LK; Sun, YL; Wang, HJ; Zhao, T; Zhao, WW, 2017
)
3.34
"Gambogic acid (GA) has been widely used as an anticancer drug for different tumors, including thyroid cancer. "( Bromodomain‑containing protein 4 is critical for the antiproliferative and pro‑apoptotic effects of gambogic acid in anaplastic thyroid cancer.
Sun, H; Wang, W; Wang, Y, 2018
)
2.14
"Gambogic acid (GA) has been approved by the Chinese Food and Drug Administration for the treatment of lung cancer in clinical trials. "( Suppression of NF-κB signaling and P-glycoprotein function by gambogic acid synergistically potentiates adriamycin -induced apoptosis in lung cancer.
Cui, W; Hou, Y; Li, Y; Ping, GF; Wang, LH; Wang, ZZ; Wu, CF; Xiao, W; Yang, JY; Yang, SN, 2014
)
2.09
"Gambogic acid (GA) has been reported to have potent anticancer activity and is authorised to be tested in phase II clinical trials for treatment of non-small-cell lung cancer (NSCLC). "( Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-κB and MAPK/HO-1 signalling.
Cao, Q; Chen, K; Cui, W; Hou, Y; Li, Y; Wang, FY; Wang, LH; Wang, S; Wang, ZZ; Wu, CF; Xiao, W; Yang, JY; Yang, SN; Zhang, TY, 2014
)
3.29
"Gambogic acid (GA) has been approved for Phase II clinical trials in cancer therapy in China."( Calcium channel blocker verapamil accelerates gambogic acid-induced cytotoxicity via enhancing proteasome inhibition and ROS generation.
Dou, QP; Huang, H; Li, X; Liu, J; Liu, N; Liu, S; Yang, C, 2014
)
1.38
"Gambogic acid has shown significant potential as an anti-cancer and anti-inflammatory compound; however, the molecular mechanism underlying the actions of gambogic acid, particularly its cellular target profiles, has not been investigated. "( Global profiling of cellular targets of gambogic acid by quantitative chemical proteomics.
Li, W; Xiao, Y; Zhang, H; Zhang, X; Zhou, Y, 2016
)
2.14
"Gambogic acid (GA) has been proven to be a potent chemotherapeutic agent for the treatment of lung cancer in clinical trials. "( Development of a More Efficient Albumin-Based Delivery System for Gambogic Acid with Low Toxicity for Lung Cancer Therapy.
Tan, X; Tang, X; Yang, Z; Zhang, Y, 2017
)
2.13
"Gambogic acid (GA) has been known to have antitumor activity in vitro and in vivo. "( Anti-invasive effect of gambogic acid in MDA-MB-231 human breast carcinoma cells.
Gu, HY; Guo, QL; Li, C; Liu, W; Lu, N; Qi, Q; Wang, XT; Yang, Y; You, QD, 2008
)
2.1
"Gambogic acid (GA) has been wildly studied to show potent anti-tumor effects in vivo and in vitro. "( Gambogic acid triggers DNA damage signaling that induces p53/p21(Waf1/CIP1) activation through the ATR-Chk1 pathway.
Guo, QL; Ha, J; Hu, R; Lu, N; Qi, Q; Rong, JJ; Song, XM; Tao, L; You, QD, 2010
)
3.25
"Gambogic acid has been demonstrated to be a highly valuable lead compound for antitumor chemotherapy."( Prenylated caged xanthones: chemistry and biology.
Anantachoke, N; Kuhakarn, C; Pohmakotr, M; Reutrakul, V; Tuchinda, P, 2012
)
1.1
"Gambogic acid (GA) has been reported as a potent apoptosis inducer. "( Synthesis and evaluation of gambogic acid derivatives as antitumor agents. Part III.
Guo, QL; Guo, XK; Jiang, C; Shen, S; Sun, HP; Sun, Y; Tao, L; Xie, FL; You, QD, 2013
)
2.13

Actions

Gambogic acid (GA) can inhibit the growth of various cancer cells. It has been shown to affect many important cell-signaling pathways.

ExcerptReferenceRelevance
"Gambogic acid (GA) can inhibit the growth of various cancer cells. "( N-octyl-N-arginine-chitosan micelles for gambogic acid intravenous delivery: characterization, cell uptake, pharmacokinetics, and biodistribution.
Jiang, F; Tang, X; Wang, B; Yu, F, 2018
)
2.19
"Gambogic acid (GA) can inhibit the growth of various cancer cells. "( N-octyl-N-arginine-chitosan (OACS) micelles for gambogic acid oral delivery: preparation, characterization and its study on in situ intestinal perfusion.
He, C; Lv, H; Munyendo, WL; Waddad, AY; Yu, F; Zhang, Q; Zhou, J, 2014
)
2.1
"Gambogic acid could inhibit proliferation of LOVO cells in a dose-dependent and time-dependent manner and induce apoptosis, which was dramatically enhanced by magnetic nanoparticles containing Fe(3)O(4). "( Synergistic effect of a combination of nanoparticulate Fe3O4 and gambogic acid on phosphatidylinositol 3-kinase/Akt/Bad pathway of LOVO cells.
Cai, X; Chen, B; Fang, L; Hu, S; Liu, S; Tian, Y; Wang, R; Xia, G, 2012
)
2.06
"Gambogic acid (GA), displays cytotoxicity towards a wide variety of tumor cells and has been shown to affect many important cell-signaling pathways. "( Gambogic acid is cytotoxic to cancer cells through inhibition of the ubiquitin-proteasome system.
Bohlin, L; D'Arcy, P; Felth, J; Fryknäs, M; Gullbo, J; Haglund, C; Larsson, R; Lesiak-Mieczkowska, K; Linder, S; Rickardson, L, 2013
)
3.28

Treatment

Gambogic acid treatment markedly decreased the levels of proinflammatory cytokines and oxidative stress factors in AAA mice. Treatment with gambogic Acid and gemcitabine significantly repressed tumor growth in the xenograft pancreatic cancer model.

ExcerptReferenceRelevance
"Gambogic acid treatment markedly decreased the levels of proinflammatory cytokines and oxidative stress factors, and transforming growth factor‑β (TGF‑β) and matrix metalloproteinase (MMP)‑2 and MMP‑9 protein expression in AAA mice."( Gambogic acid prevents angiotensin II‑induced abdominal aortic aneurysm through inflammatory and oxidative stress dependent targeting the PI3K/Akt/mTOR and NF‑κB signaling pathways.
Li, H; Liu, Q; Shan, P, 2019
)
2.68
"Treatment of gambogic acid with methanol in acidic condition under microwave irradiation led to the formation of two new products bearing spectacular A ring systems which were different from reported Garcinia natural products. "( Spectacular modification of Gambogic acid on microwave irradiation in methanol: isolation and structure identification of two products with potent anti-tumor activity.
Dai, Q; Guo, Q; Guo, X; Lu, N; Tao, L; Wang, X; Yang, Q; You, Q, 2010
)
1.02
"Treatment with gambogic acid and gemcitabine significantly repressed tumor growth in the xenograft pancreatic cancer model."( Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2).
Huang, X; Meng, Q; Song, Z; Wang, H; Xia, G, 2017
)
2.24
"Treatment with gambogic acid suppressed the activities of interleukin (IL)‑1β and IL‑6, promoted the protein expression of phosphorylated (p)‑Akt serine/threonine kinase (Akt), p‑mammalian target protein of rapamycin (mTOR) and inhibited hypoxia‑inducible factor‑1α and vascular endothelial growth factor expression in RA rats."( Gambogic acid suppresses inflammation in rheumatoid arthritis rats via PI3K/Akt/mTOR signaling pathway.
Chen, X; Liu, J; Long, L; Lv, TZ; Wu, T; Wu, X; Zhang, J; Zhou, B, 2017
)
2.24
"Treatment with gambogic acid effectively improved BBB scores and inhibited water content of the spinal cord in SCI rats."( Gambogic acid inhibits spinal cord injury and inflammation through suppressing the p38 and Akt signaling pathways.
Fu, Q; Li, C; Yu, L, 2018
)
2.26

Toxicity

ExcerptReferenceRelevance
" In addition, we found a concentration of GA that is toxic to malignant hematopoietic cells but not to human hematopoietic progenitor cells."( Enhanced cytotoxicity of an anti-transferrin receptor IgG3-avidin fusion protein in combination with gambogic acid against human malignant hematopoietic cells: functional relevance of iron, the receptor, and reactive oxygen species.
Bonavida, B; Daniels, TR; Helguera, G; Martinez-Maza, O; Ortiz-Sánchez, E; Penichet, ML, 2009
)
0.57
" Results showed that GA did not cause any toxic symptoms on blood pressure (i."( General pharmacological properties, developmental toxicity, and analgesic activity of gambogic acid, a novel natural anticancer agent.
Guo, Q; Hu, R; Wu, Z; Zhao, L; Zhen, C; Zhou, C, 2010
)
0.58
" Intravenous injection and oral administration of GA induced remarkable pathological changes in various organs in mice, whereas GA was not toxic to various organs or to the skin via topical delivery."( New Delivery Route of Gambogic Acid Via Skin for Topical Targeted Therapy of Cutaneous Melanoma and Reduction of Systemic Toxicity.
Hou, T; Pang, Y; Wang, C; Wang, Q; Wang, W; Wu, S; Zhang, D, 2021
)
0.94

Pharmacokinetics

ExcerptReferenceRelevance
" The established method has been successfully applied to a pharmacokinetic study of gambogic acid in dogs."( Determination of gambogic acid in dog plasma by high-performance liquid chromatography for a pharmacokinetic study.
Hao, K; Liu, XQ; Wang, GJ; Zhao, XP, 2007
)
0.9
" The elimination half-life (tl/2) values for GA were estimated to be 14."( Pharmacokinetics, tissue distribution and excretion of gambogic acid in rats.
Hao, K; Liu, XQ; Wang, GJ; Zhao, XP,
)
0.38
" However, the short elimination half-life time and treatment without targeting limits its application."( N-octyl-N-arginine-chitosan micelles for gambogic acid intravenous delivery: characterization, cell uptake, pharmacokinetics, and biodistribution.
Jiang, F; Tang, X; Wang, B; Yu, F, 2018
)
0.75

Compound-Compound Interactions

The purpose of this study was to determine the potential benefits of combination therapy using dimercaptosuccinic acid modified iron oxide (DMSA-Fe3O4) magnetic nanoparticles (MNPs) combined with nontoxic concentration of bortezomib (BTZ) and gambogic acid (GA)

ExcerptReferenceRelevance
"To evaluated the effect of the gambogic acid (GA), one of the effective components of Garcinia, in combination with a new multi-targeted oral medication, sunitinib (SU) on renal cancer cell proliferation in vitro and on tumor growth in vivo."( Targeting renal cell carcinoma with gambogic acid in combination with sunitinib in vitro and in vivo.
Jiang, XL; Luo, CL; Wu, XH; Zhang, Y, 2012
)
0.94
" Immunohistochemistry arrays showed downregulation of the expression of proteins promoting xenograft growth and angiogenesis, and Western blotting showed inhibition of the NF-?B signaling pathway after treatment by GA alone and in combination with SU in xenografts."( Targeting renal cell carcinoma with gambogic acid in combination with sunitinib in vitro and in vivo.
Jiang, XL; Luo, CL; Wu, XH; Zhang, Y, 2012
)
0.65
"The purpose of this study was to determine the potential benefits of combination therapy using dimercaptosuccinic acid modified iron oxide (DMSA-Fe3O4) magnetic nanoparticles (MNPs) combined with nontoxic concentration of bortezomib (BTZ) and gambogic acid (GA) on multiple myeloma (MM) RPMI-8226 cells and possible underlying mechanisms."( Inducing cell cycle arrest and apoptosis by dimercaptosuccinic acid modified Fe3O4 magnetic nanoparticles combined with nontoxic concentration of bortezomib and gambogic acid in RPMI-8226 cells.
Chen, B; Qiao, L; Senthilkumar, R; Wang, F; Wang, X; Zhang, W, 2015
)
0.8

Bioavailability

ExcerptReferenceRelevance
"GA can be absorbed in all intestinal segments in rats with the higher absorption rate in duodenum."( [Study on intestinal absorption kinetics of gambogic acid in rats].
Lv, H; Waddad, AY; Wang, X; Yu, F; Zhou, J, 2012
)
0.64
" However, the low bioavailability caused by insolubility, limits its clinical application."( N-octyl-N-arginine-chitosan (OACS) micelles for gambogic acid oral delivery: preparation, characterization and its study on in situ intestinal perfusion.
He, C; Lv, H; Munyendo, WL; Waddad, AY; Yu, F; Zhang, Q; Zhou, J, 2014
)
0.66
" Pharmacokinetic studies indicated that the superior antitumor efficacy of GA-P2 was attributed not only to tissue targeting but also to low clearance, extended retention, high bioavailability in plasma, and increased GA stability."( Gambogic acid-loaded electrosprayed particles for site-specific treatment of hepatocellular carcinoma.
Cai, H; He, L; Peng, D; Wang, F; Yang, Y; Yin, D, 2014
)
1.85
" This validated method was firstly applied to bioavailability (BA), pharmacokinetics, excretion and tissue distribution in rats."( UHPLC-MS method for determination of gambogic acid and application to bioavailability, pharmacokinetics, excretion and tissue distribution in rats.
Li, Y; Ou, W; Zhang, X; Zheng, Z, 2015
)
0.69
" The supramolecular nanocomplex provide a promising platform for the delivery of hydrophobic chemotherapeutics to improve the bioavailability and efficiency."( Inclusion complex from cyclodextrin-grafted hyaluronic acid and pseudo protein as biodegradable nano-delivery vehicle for gambogic acid.
Chu, CC; He, M; Ji, Y; Shan, S, 2017
)
0.66
" To achieve better bioavailability of antitumor drugs that were loaded in RBCm-NPs, the functionalization of coated RBCm with specific targeting ability is essential."( Anti-EGFR-iRGD recombinant protein modified biomimetic nanoparticles loaded with gambogic acid to enhance targeting and antitumor ability in colorectal cancer treatment.
Hua, D; Huang, J; Liu, B; Qian, H; Qian, X; Sha, H; Yu, L; Zhang, H; Zhang, Z, 2018
)
0.71
" However, these systems still face certain challenges such as codelivery of drugs with different chemistries, inadequate loading efficiency, immune rejection resulting in rapid clearance and substantially poor bioavailability in vivo."( Bioinspired red blood cell membrane-encapsulated biomimetic nanoconstructs for synergistic and efficacious chemo-photothermal therapy.
Cai, D; Chen, B; Jiang, F; Kankala, RK; Liu, Y; Long, R; Tang, H; Wang, P; Wang, S; Yang, D; Zeng, X; Zhu, M, 2020
)
0.56
" So far, GA has been utilized to develop a variety of active derivatives with improved water solubility and bioavailability through structural modification."( Research Progress in the Field of Gambogic Acid and Its Derivatives as Antineoplastic Drugs.
Li, J; Li, M; Lv, S; Su, F; Wei, Y; Zhang, H; Zhao, Y; Zhu, M, 2022
)
1
"Inspired by the critical role of nanocarrier in biomaterials modification, we synthesized a mesoporous rod-structure hydroxyapatite (MR-HAp) nanoparticles for boosting gambogic acid (GA) bioavailability in cells and improving the tumor therapy."( Sustained delivery of gambogic acid from mesoporous rod-structure hydroxyapatite for efficient in vitro cancer therapy.
Chen, J; Guan, S; Liu, S; Wang, J; Zhang, T, 2022
)
1.23
" Compared to free GA, the optimized PEUU nanocarrier improves the intratumoral distribution of GA by more than 9-fold, which significantly enhances the bioavailability and persistence of GA after intravenous administration."( Optimization of amino acid-based poly(ester urea urethane) nanoparticles for the systemic delivery of gambogic acid for treating triple negative breast cancer.
Bian, Z; Chu, CC; Ji, Y; Kwan, HY; Li, J; Xiao, S, 2023
)
1.13

Dosage Studied

ExcerptRelevanceReference
"1 (body surface area) times the dosage (25 mg/60 kg, every other day) recommended for human trials."( Toxicological studies of gambogic acid and its potential targets in experimental animals.
Gu, H; Guo, Q; Qi, Q; Wu, Z; You, Q; Zhao, L, 2006
)
0.64
" Based on the preliminary results of a phase I study, this phase IIa study compared the efficacy and safety of different dosage schedules of gambogic acid in patients with advanced malignant tumors."( An open-labeled, randomized, multicenter phase IIa study of gambogic acid injection for advanced malignant tumors.
Chi, Y; Cui, CX; Hu, JF; Wang, JW; Wang, YG; Wang, ZZ; Xiao, W; Xie, GR; Xiong, FX; Yang, L; Yu, H; Zhan, XK, 2013
)
0.83
" In addition, we have developed a rapid, inexpensive means to evaluate response following drug treatment where spheroid dissolution indices from brightfield image analyses are used to construct dose-response curves resulting in relevant IC50 values."( Spontaneously-forming spheroids as an in vitro cancer cell model for anticancer drug screening.
Alpaugh, ML; Chantarasriwong, O; Corben, AD; Rezende, CO; Theodoraki, MA; Theodorakis, EA, 2015
)
0.42
" PAG can self-assemble into micelles as amphiphilic block copolymers, which exhibits an excellent loading ability for the co-delivery of docetaxel (DTX) and MMP-9 shRNA with adjustable dosing ratios."( Redox-responsive polymeric micelles formed by conjugating gambogic acid with bioreducible poly(amido amine)s for the co-delivery of docetaxel and MMP-9 shRNA.
Ding, Y; Ho, RJY; Kang, Y; Lan, J; Lu, L; Yang, J; Zhang, T; Zhang, Y; Zhao, Y, 2018
)
0.73
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
pyranoxanthonesAny organic heterotetracyclic compound that consists of a pyran ring fused onto a xanthone skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (7)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Inhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)IC50 (µMol)3.07000.00090.97819.8200AID648823
Heat shock protein HSP 90-alphaHomo sapiens (human)IC50 (µMol)21.98000.00040.695010.0000AID1632347
ThioredoxinHomo sapiens (human)Ki3.11003.11003.11003.1100AID716711
Tyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)IC50 (µMol)0.47000.00053.49849.7600AID1456320
Tyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)Ki0.34450.19004.83279.6000AID1456323; AID1456332
Thioredoxin, mitochondrialHomo sapiens (human)Ki1.31001.31001.31001.3100AID716710
Regulator of G-protein signaling 17Homo sapiens (human)IC50 (µMol)11.01671.38605.936310.0000AID1377215; AID1618223; AID1618224
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Heat shock protein HSP 90-alphaHomo sapiens (human)Kd8.13330.00030.94889.8000AID606957; AID606958; AID606995
Heat shock protein HSP 90-betaHomo sapiens (human)Kd8.13330.00031.33309.8000AID606957; AID606958; AID606995
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (130)

Processvia Protein(s)Taxonomy
positive regulation of NF-kappaB transcription factor activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
stimulatory C-type lectin receptor signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependentInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
MyD88-dependent toll-like receptor signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein phosphorylationInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
inflammatory responseInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
canonical NF-kappaB signal transductionInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
response to virusInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
regulation of tumor necrosis factor-mediated signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
peptidyl-serine phosphorylationInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
cortical actin cytoskeleton organizationInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
tumor necrosis factor-mediated signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
toll-like receptor 3 signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
negative regulation of myosin-light-chain-phosphatase activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
TRIF-dependent toll-like receptor signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
Fc-epsilon receptor signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
regulation of phosphorylationInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
innate immune responseInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
positive regulation of DNA-templated transcriptionInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
T cell receptor signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
stress-activated MAPK cascadeInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein maturationInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
interleukin-1-mediated signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
cellular response to tumor necrosis factorInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein localization to plasma membraneInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
regulation of establishment of endothelial barrierInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
negative regulation of bicellular tight junction assemblyInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
regulation of toll-like receptor signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
telomere maintenance via telomeraseHeat shock protein HSP 90-alphaHomo sapiens (human)
neuron migrationHeat shock protein HSP 90-alphaHomo sapiens (human)
positive regulation of protein phosphorylationHeat shock protein HSP 90-alphaHomo sapiens (human)
activation of innate immune responseHeat shock protein HSP 90-alphaHomo sapiens (human)
positive regulation of defense response to virus by hostHeat shock protein HSP 90-alphaHomo sapiens (human)
skeletal muscle contractionHeat shock protein HSP 90-alphaHomo sapiens (human)
mitochondrial transportHeat shock protein HSP 90-alphaHomo sapiens (human)
response to unfolded proteinHeat shock protein HSP 90-alphaHomo sapiens (human)
response to heatHeat shock protein HSP 90-alphaHomo sapiens (human)
response to coldHeat shock protein HSP 90-alphaHomo sapiens (human)
response to xenobiotic stimulusHeat shock protein HSP 90-alphaHomo sapiens (human)
response to salt stressHeat shock protein HSP 90-alphaHomo sapiens (human)
positive regulation of lamellipodium assemblyHeat shock protein HSP 90-alphaHomo sapiens (human)
cardiac muscle cell apoptotic processHeat shock protein HSP 90-alphaHomo sapiens (human)
regulation of protein ubiquitinationHeat shock protein HSP 90-alphaHomo sapiens (human)
positive regulation of protein polymerizationHeat shock protein HSP 90-alphaHomo sapiens (human)
positive regulation of interferon-beta productionHeat shock protein HSP 90-alphaHomo sapiens (human)
regulation of protein localizationHeat shock protein HSP 90-alphaHomo sapiens (human)
protein refoldingHeat shock protein HSP 90-alphaHomo sapiens (human)
response to cocaineHeat shock protein HSP 90-alphaHomo sapiens (human)
positive regulation of protein import into nucleusHeat shock protein HSP 90-alphaHomo sapiens (human)
regulation of apoptotic processHeat shock protein HSP 90-alphaHomo sapiens (human)
regulation of protein-containing complex assemblyHeat shock protein HSP 90-alphaHomo sapiens (human)
protein unfoldingHeat shock protein HSP 90-alphaHomo sapiens (human)
response to estrogenHeat shock protein HSP 90-alphaHomo sapiens (human)
protein insertion into mitochondrial outer membraneHeat shock protein HSP 90-alphaHomo sapiens (human)
positive regulation of nitric oxide biosynthetic processHeat shock protein HSP 90-alphaHomo sapiens (human)
positive regulation of protein catabolic processHeat shock protein HSP 90-alphaHomo sapiens (human)
positive regulation of cell sizeHeat shock protein HSP 90-alphaHomo sapiens (human)
response to antibioticHeat shock protein HSP 90-alphaHomo sapiens (human)
protein stabilizationHeat shock protein HSP 90-alphaHomo sapiens (human)
chaperone-mediated protein complex assemblyHeat shock protein HSP 90-alphaHomo sapiens (human)
positive regulation of cardiac muscle contractionHeat shock protein HSP 90-alphaHomo sapiens (human)
chaperone-mediated autophagyHeat shock protein HSP 90-alphaHomo sapiens (human)
cellular response to virusHeat shock protein HSP 90-alphaHomo sapiens (human)
regulation of postsynaptic membrane neurotransmitter receptor levelsHeat shock protein HSP 90-alphaHomo sapiens (human)
positive regulation of tau-protein kinase activityHeat shock protein HSP 90-alphaHomo sapiens (human)
telomerase holoenzyme complex assemblyHeat shock protein HSP 90-alphaHomo sapiens (human)
cellular response to heatHeat shock protein HSP 90-alphaHomo sapiens (human)
protein foldingHeat shock protein HSP 90-alphaHomo sapiens (human)
telomere maintenance via telomeraseHeat shock protein HSP 90-betaHomo sapiens (human)
placenta developmentHeat shock protein HSP 90-betaHomo sapiens (human)
response to unfolded proteinHeat shock protein HSP 90-betaHomo sapiens (human)
virion attachment to host cellHeat shock protein HSP 90-betaHomo sapiens (human)
positive regulation of transforming growth factor beta receptor signaling pathwayHeat shock protein HSP 90-betaHomo sapiens (human)
regulation of protein ubiquitinationHeat shock protein HSP 90-betaHomo sapiens (human)
negative regulation of proteasomal ubiquitin-dependent protein catabolic processHeat shock protein HSP 90-betaHomo sapiens (human)
positive regulation of phosphoprotein phosphatase activityHeat shock protein HSP 90-betaHomo sapiens (human)
regulation of protein localizationHeat shock protein HSP 90-betaHomo sapiens (human)
negative regulation of apoptotic processHeat shock protein HSP 90-betaHomo sapiens (human)
positive regulation of nitric oxide biosynthetic processHeat shock protein HSP 90-betaHomo sapiens (human)
positive regulation of cell differentiationHeat shock protein HSP 90-betaHomo sapiens (human)
chaperone-mediated protein complex assemblyHeat shock protein HSP 90-betaHomo sapiens (human)
regulation of cell cycleHeat shock protein HSP 90-betaHomo sapiens (human)
chaperone-mediated protein foldingHeat shock protein HSP 90-betaHomo sapiens (human)
cellular response to interleukin-4Heat shock protein HSP 90-betaHomo sapiens (human)
supramolecular fiber organizationHeat shock protein HSP 90-betaHomo sapiens (human)
negative regulation of proteasomal protein catabolic processHeat shock protein HSP 90-betaHomo sapiens (human)
telomerase holoenzyme complex assemblyHeat shock protein HSP 90-betaHomo sapiens (human)
positive regulation of protein localization to cell surfaceHeat shock protein HSP 90-betaHomo sapiens (human)
cellular response to heatHeat shock protein HSP 90-betaHomo sapiens (human)
protein foldingHeat shock protein HSP 90-betaHomo sapiens (human)
protein stabilizationHeat shock protein HSP 90-betaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIThioredoxinHomo sapiens (human)
response to radiationThioredoxinHomo sapiens (human)
activation of protein kinase B activityThioredoxinHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationThioredoxinHomo sapiens (human)
positive regulation of DNA bindingThioredoxinHomo sapiens (human)
cell redox homeostasisThioredoxinHomo sapiens (human)
negative regulation of protein export from nucleusThioredoxinHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionThioredoxinHomo sapiens (human)
cellular detoxification of hydrogen peroxideThioredoxinHomo sapiens (human)
response to nitric oxideThioredoxinHomo sapiens (human)
positive regulation of peptidyl-cysteine S-nitrosylationThioredoxinHomo sapiens (human)
positive regulation of JUN kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
actin cytoskeleton organizationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of endocytosisTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of vascular endothelial growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulum unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of intracellular protein transportTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cellular response to unfolded proteinTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
platelet-derived growth factor receptor-beta signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor recyclingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of MAP kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of type I interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of protein tyrosine kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of hepatocyte growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of PERK-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylation involved in inactivation of protein kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of receptor catabolic processTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
response to hypoxiaThioredoxin, mitochondrialHomo sapiens (human)
response to oxidative stressThioredoxin, mitochondrialHomo sapiens (human)
response to xenobiotic stimulusThioredoxin, mitochondrialHomo sapiens (human)
response to hormoneThioredoxin, mitochondrialHomo sapiens (human)
response to glucoseThioredoxin, mitochondrialHomo sapiens (human)
response to organic cyclic compoundThioredoxin, mitochondrialHomo sapiens (human)
cellular response to nutrient levelsThioredoxin, mitochondrialHomo sapiens (human)
response to axon injuryThioredoxin, mitochondrialHomo sapiens (human)
cell redox homeostasisThioredoxin, mitochondrialHomo sapiens (human)
response to amphetamineRegulator of G-protein signaling 17Homo sapiens (human)
G protein-coupled receptor signaling pathwayRegulator of G-protein signaling 17Homo sapiens (human)
negative regulation of signal transductionRegulator of G-protein signaling 17Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (62)

Processvia Protein(s)Taxonomy
protein kinase activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein serine/threonine kinase activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein bindingInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
ATP bindingInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
IkappaB kinase activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein kinase bindingInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
identical protein bindingInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein homodimerization activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein heterodimerization activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
scaffold protein bindingInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein serine kinase activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
transferrin receptor bindingInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
UTP bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
CTP bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
RNA bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
mRNA bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
protein bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
ATP bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
GTP bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
ATP hydrolysis activityHeat shock protein HSP 90-alphaHomo sapiens (human)
sulfonylurea receptor bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
protein phosphatase bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
MHC class II protein complex bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
nitric-oxide synthase regulator activityHeat shock protein HSP 90-alphaHomo sapiens (human)
TPR domain bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
ubiquitin protein ligase bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
dATP bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
identical protein bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
protein homodimerization activityHeat shock protein HSP 90-alphaHomo sapiens (human)
histone deacetylase bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
transmembrane transporter bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
tau protein bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
GTPase bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
Rho GDP-dissociation inhibitor bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
DNA polymerase bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
scaffold protein bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
disordered domain specific bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
ATP-dependent protein folding chaperoneHeat shock protein HSP 90-alphaHomo sapiens (human)
protein tyrosine kinase bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
unfolded protein bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
RNA bindingHeat shock protein HSP 90-betaHomo sapiens (human)
double-stranded RNA bindingHeat shock protein HSP 90-betaHomo sapiens (human)
protein bindingHeat shock protein HSP 90-betaHomo sapiens (human)
ATP bindingHeat shock protein HSP 90-betaHomo sapiens (human)
ATP hydrolysis activityHeat shock protein HSP 90-betaHomo sapiens (human)
protein kinase regulator activityHeat shock protein HSP 90-betaHomo sapiens (human)
kinase bindingHeat shock protein HSP 90-betaHomo sapiens (human)
protein kinase bindingHeat shock protein HSP 90-betaHomo sapiens (human)
MHC class II protein complex bindingHeat shock protein HSP 90-betaHomo sapiens (human)
nitric-oxide synthase regulator activityHeat shock protein HSP 90-betaHomo sapiens (human)
TPR domain bindingHeat shock protein HSP 90-betaHomo sapiens (human)
heat shock protein bindingHeat shock protein HSP 90-betaHomo sapiens (human)
ubiquitin protein ligase bindingHeat shock protein HSP 90-betaHomo sapiens (human)
peptide bindingHeat shock protein HSP 90-betaHomo sapiens (human)
identical protein bindingHeat shock protein HSP 90-betaHomo sapiens (human)
protein homodimerization activityHeat shock protein HSP 90-betaHomo sapiens (human)
histone deacetylase bindingHeat shock protein HSP 90-betaHomo sapiens (human)
ATP-dependent protein bindingHeat shock protein HSP 90-betaHomo sapiens (human)
protein folding chaperoneHeat shock protein HSP 90-betaHomo sapiens (human)
cadherin bindingHeat shock protein HSP 90-betaHomo sapiens (human)
protein dimerization activityHeat shock protein HSP 90-betaHomo sapiens (human)
tau protein bindingHeat shock protein HSP 90-betaHomo sapiens (human)
DNA polymerase bindingHeat shock protein HSP 90-betaHomo sapiens (human)
disordered domain specific bindingHeat shock protein HSP 90-betaHomo sapiens (human)
ATP-dependent protein folding chaperoneHeat shock protein HSP 90-betaHomo sapiens (human)
receptor ligand inhibitor activityHeat shock protein HSP 90-betaHomo sapiens (human)
histone methyltransferase bindingHeat shock protein HSP 90-betaHomo sapiens (human)
unfolded protein bindingHeat shock protein HSP 90-betaHomo sapiens (human)
RNA bindingThioredoxinHomo sapiens (human)
thioredoxin-disulfide reductase (NADPH) activityThioredoxinHomo sapiens (human)
protein bindingThioredoxinHomo sapiens (human)
protein-disulfide reductase activityThioredoxinHomo sapiens (human)
protein homodimerization activityThioredoxinHomo sapiens (human)
protein-disulfide reductase (NAD(P)H) activityThioredoxinHomo sapiens (human)
RNA bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
zinc ion bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
enzyme bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
receptor tyrosine kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cadherin bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
ephrin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein phosphatase 2A bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein bindingThioredoxin, mitochondrialHomo sapiens (human)
peptide-methionine (S)-S-oxide reductase activityThioredoxin, mitochondrialHomo sapiens (human)
protein-disulfide reductase activityThioredoxin, mitochondrialHomo sapiens (human)
peptide-methionine (R)-S-oxide reductase activityThioredoxin, mitochondrialHomo sapiens (human)
protein-containing complex bindingThioredoxin, mitochondrialHomo sapiens (human)
GTPase activityRegulator of G-protein signaling 17Homo sapiens (human)
GTPase activator activityRegulator of G-protein signaling 17Homo sapiens (human)
protein bindingRegulator of G-protein signaling 17Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (47)

Processvia Protein(s)Taxonomy
cytoplasmInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
nucleusInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
cytosolInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
IkappaB kinase complexInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
cytoplasmic side of plasma membraneInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
membrane raftInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
CD40 receptor complexInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
extracellular regionHeat shock protein HSP 90-alphaHomo sapiens (human)
nucleusHeat shock protein HSP 90-alphaHomo sapiens (human)
nucleoplasmHeat shock protein HSP 90-alphaHomo sapiens (human)
cytoplasmHeat shock protein HSP 90-alphaHomo sapiens (human)
mitochondrionHeat shock protein HSP 90-alphaHomo sapiens (human)
cytosolHeat shock protein HSP 90-alphaHomo sapiens (human)
plasma membraneHeat shock protein HSP 90-alphaHomo sapiens (human)
cell surfaceHeat shock protein HSP 90-alphaHomo sapiens (human)
membraneHeat shock protein HSP 90-alphaHomo sapiens (human)
basolateral plasma membraneHeat shock protein HSP 90-alphaHomo sapiens (human)
apical plasma membraneHeat shock protein HSP 90-alphaHomo sapiens (human)
brush border membraneHeat shock protein HSP 90-alphaHomo sapiens (human)
secretory granule lumenHeat shock protein HSP 90-alphaHomo sapiens (human)
melanosomeHeat shock protein HSP 90-alphaHomo sapiens (human)
neuronal cell bodyHeat shock protein HSP 90-alphaHomo sapiens (human)
lysosomal lumenHeat shock protein HSP 90-alphaHomo sapiens (human)
dendritic growth coneHeat shock protein HSP 90-alphaHomo sapiens (human)
axonal growth coneHeat shock protein HSP 90-alphaHomo sapiens (human)
perinuclear region of cytoplasmHeat shock protein HSP 90-alphaHomo sapiens (human)
collagen-containing extracellular matrixHeat shock protein HSP 90-alphaHomo sapiens (human)
extracellular exosomeHeat shock protein HSP 90-alphaHomo sapiens (human)
endocytic vesicle lumenHeat shock protein HSP 90-alphaHomo sapiens (human)
sperm mitochondrial sheathHeat shock protein HSP 90-alphaHomo sapiens (human)
sperm plasma membraneHeat shock protein HSP 90-alphaHomo sapiens (human)
ficolin-1-rich granule lumenHeat shock protein HSP 90-alphaHomo sapiens (human)
protein-containing complexHeat shock protein HSP 90-alphaHomo sapiens (human)
plasma membraneHeat shock protein HSP 90-alphaHomo sapiens (human)
neuronal cell bodyHeat shock protein HSP 90-alphaHomo sapiens (human)
perinuclear region of cytoplasmHeat shock protein HSP 90-alphaHomo sapiens (human)
myelin sheathHeat shock protein HSP 90-alphaHomo sapiens (human)
cytosolHeat shock protein HSP 90-alphaHomo sapiens (human)
nucleusHeat shock protein HSP 90-alphaHomo sapiens (human)
COP9 signalosomeHeat shock protein HSP 90-betaHomo sapiens (human)
protein folding chaperone complexHeat shock protein HSP 90-betaHomo sapiens (human)
extracellular regionHeat shock protein HSP 90-betaHomo sapiens (human)
nucleusHeat shock protein HSP 90-betaHomo sapiens (human)
nucleoplasmHeat shock protein HSP 90-betaHomo sapiens (human)
cytoplasmHeat shock protein HSP 90-betaHomo sapiens (human)
mitochondrionHeat shock protein HSP 90-betaHomo sapiens (human)
cytosolHeat shock protein HSP 90-betaHomo sapiens (human)
cell surfaceHeat shock protein HSP 90-betaHomo sapiens (human)
membraneHeat shock protein HSP 90-betaHomo sapiens (human)
secretory granule lumenHeat shock protein HSP 90-betaHomo sapiens (human)
melanosomeHeat shock protein HSP 90-betaHomo sapiens (human)
neuronal cell bodyHeat shock protein HSP 90-betaHomo sapiens (human)
dendritic growth coneHeat shock protein HSP 90-betaHomo sapiens (human)
axonal growth coneHeat shock protein HSP 90-betaHomo sapiens (human)
perinuclear region of cytoplasmHeat shock protein HSP 90-betaHomo sapiens (human)
extracellular exosomeHeat shock protein HSP 90-betaHomo sapiens (human)
dynein axonemal particleHeat shock protein HSP 90-betaHomo sapiens (human)
ficolin-1-rich granule lumenHeat shock protein HSP 90-betaHomo sapiens (human)
protein-containing complexHeat shock protein HSP 90-betaHomo sapiens (human)
aryl hydrocarbon receptor complexHeat shock protein HSP 90-betaHomo sapiens (human)
HSP90-CDC37 chaperone complexHeat shock protein HSP 90-betaHomo sapiens (human)
perinuclear region of cytoplasmHeat shock protein HSP 90-betaHomo sapiens (human)
plasma membraneHeat shock protein HSP 90-betaHomo sapiens (human)
cytosolHeat shock protein HSP 90-betaHomo sapiens (human)
extracellular regionThioredoxinHomo sapiens (human)
nucleusThioredoxinHomo sapiens (human)
nucleoplasmThioredoxinHomo sapiens (human)
cytoplasmThioredoxinHomo sapiens (human)
cytosolThioredoxinHomo sapiens (human)
extracellular exosomeThioredoxinHomo sapiens (human)
plasma membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial matrixTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial cristaTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endosome lumenTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
sorting endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmic side of endoplasmic reticulum membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein-containing complexTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
nucleolusThioredoxin, mitochondrialHomo sapiens (human)
mitochondrionThioredoxin, mitochondrialHomo sapiens (human)
mitochondrial matrixThioredoxin, mitochondrialHomo sapiens (human)
dendriteThioredoxin, mitochondrialHomo sapiens (human)
neuronal cell bodyThioredoxin, mitochondrialHomo sapiens (human)
mitochondrionThioredoxin, mitochondrialHomo sapiens (human)
nucleusRegulator of G-protein signaling 17Homo sapiens (human)
cytoplasmRegulator of G-protein signaling 17Homo sapiens (human)
plasma membraneRegulator of G-protein signaling 17Homo sapiens (human)
neuron projectionRegulator of G-protein signaling 17Homo sapiens (human)
synapseRegulator of G-protein signaling 17Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (267)

Assay IDTitleYearJournalArticle
AID662807Cytotoxicity against human KB cells by MTT assay2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Design and synthesis of gambogic acid analogs as potent cytotoxic and anti-inflammatory agents.
AID730913Half life in CD1 mouse at 20 mg/kg, po by LCMS/MS analysis2013Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1
Garcinia xanthones as orally active antitumor agents.
AID592412Anticancer activity aganist human HT-29 cells2011Journal of natural products, Mar-25, Volume: 74, Issue:3
Absolute configuration of (-)-gambogic acid, an antitumor agent.
AID1207021Intrinsic aqueous solubility of the compound by potentiometric titration method2015Bioorganic & medicinal chemistry letters, Jun-15, Volume: 25, Issue:12
Novel natural-product-like caged xanthones with improved druglike properties and in vivo antitumor potency.
AID730911Mean residence time in CD1 mouse at 20 mg/kg, po by LCMS/MS analysis2013Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1
Garcinia xanthones as orally active antitumor agents.
AID648760Inhibition of NF-kappaB activation in human A549 cells assessed as inhibition of TNFalpha/IFNgamma/IL-1beta-induced NF-kappaB nuclear translocation at 5 uM treated 2 hrs before TNFalpha/IFNgamma/IL-1beta stimulation measured after 30 mins2012European journal of medicinal chemistry, May, Volume: 51Studies on gambogic acid (IV): Exploring structure-activity relationship with IκB kinase-beta (IKKβ).
AID1207020Cytotoxicity against human U251 cells assessed as growth inhibition after 24 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Jun-15, Volume: 25, Issue:12
Novel natural-product-like caged xanthones with improved druglike properties and in vivo antitumor potency.
AID419841Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay2009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
Studies on chemical structure modification and biology of a natural product, gambogic acid (I): Synthesis and biological evaluation of oxidized analogues of gambogic acid.
AID730918Half life in CD1 mouse at 5 mg/kg, iv by LCMS/MS analysis2013Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1
Garcinia xanthones as orally active antitumor agents.
AID329547Stimulation of TrkA dimerization co-transfected in HEK293 cells at 0.5 uM after 30 mins by immunoblotting analysis in presence of green fluorescent protein2007Proceedings of the National Academy of Sciences of the United States of America, Oct-09, Volume: 104, Issue:41
Gambogic amide, a selective agonist for TrkA receptor that possesses robust neurotrophic activity, prevents neuronal cell death.
AID1216626Drug level in Sprague-Dawley rat feces at 4 mg/kg, iv measured over 24 hrs by LC-MS/MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Metabolism of gambogic acid in rats: a rare intestinal metabolic pathway responsible for its final disposition.
AID648827Induction of apoptosis in human U251 cells assessed as morphological changes at 8 uM after 24 hrs by inverted light microscopic analysis2012European journal of medicinal chemistry, May, Volume: 51Studies on gambogic acid (IV): Exploring structure-activity relationship with IκB kinase-beta (IKKβ).
AID419839Cytotoxicity against human BGC823 cells after 48 hrs by MTT assay2009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
Studies on chemical structure modification and biology of a natural product, gambogic acid (I): Synthesis and biological evaluation of oxidized analogues of gambogic acid.
AID329570Neuroprotective effect in rat MCAO model assessed as decrease in cerebral blood flow at 2 mg/kg within 5 mins2007Proceedings of the National Academy of Sciences of the United States of America, Oct-09, Volume: 104, Issue:41
Gambogic amide, a selective agonist for TrkA receptor that possesses robust neurotrophic activity, prevents neuronal cell death.
AID1594145Inhibition of Escherichia coli GroEL expressed in Escherichia coli DH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured rhodanese refolding by measuring rhodanese enzyme activity 2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1216642Drug metabolism in rat liver microsomes assessed as CYP450-mediated 10-OHGA formation at 50 uM preincubated for 10 mins followed by NADPH addition measured after 1 hr by LC-DAD-MS/MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Metabolism of gambogic acid in rats: a rare intestinal metabolic pathway responsible for its final disposition.
AID1656234Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay2019European journal of medicinal chemistry, Feb-15, Volume: 164Green recipes to quinoline: A review.
AID638227Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Synthesis and biological evaluation of novel derivatives of gambogic acid as anti-hepatocellular carcinoma agents.
AID730915Tmax in CD1 mouse at 20 mg/kg, po by LCMS/MS analysis2013Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1
Garcinia xanthones as orally active antitumor agents.
AID1271464Induction of apoptosis in human T98G cells assessed as increase of cleaved caspase-8 level at 200 to 400 nM after 10 to 24 hrs by Western blot analysis2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
Gambogic acid induces apoptotic cell death in T98G glioma cells.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID736737Inhibition of human MDM2-p53 interaction expressed in Saccharomyces cerevisiae CG379 assessed as reversal of MDM2-dependent inhibition of p53-induced S-phase cell cycle arrest at 10 uM after 42 hrs by Sytox Green-based flow cytometric analysis2013Journal of natural products, Apr-26, Volume: 76, Issue:4
Α-mangostin and gambogic acid as potential inhibitors of the p53-MDM2 interaction revealed by a yeast approach.
AID1169350Selectivity index, ratio of cytotoxic EC50 against human cells to EC50 for Plasmodium falciparum 3D72014Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22
Antimalarial activity of abietane ferruginol analogues possessing a phthalimide group.
AID730914AUC in CD1 mouse at 5 mg/kg, iv by LCMS/MS analysis2013Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1
Garcinia xanthones as orally active antitumor agents.
AID1456343Ratio of Ki for competitive inhibition of recombinant human PTP1B (1 to 322 residues) expressed in Escherichia coli at 24.8 uM to Ki for non-competitive inhibition of recombinant human PTP1B (1 to 322 residues) expressed in Escherichia coli at 24.8 uM
AID1271468Induction of apoptosis in human T98G cells assessed as increase of AIF level at 200 to 400 nM after 10 to 24 hrs by Western blot analysis2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
Gambogic acid induces apoptotic cell death in T98G glioma cells.
AID1456322Competitive inhibition of recombinant human PTP1B (1 to 322 residues) expressed in Escherichia coli at 12.4 to 49.6 uM using pNPP as substrate by Line-weaver burk plot method
AID329561Induction of MAPK phosphorylation in human T17 cells2007Proceedings of the National Academy of Sciences of the United States of America, Oct-09, Volume: 104, Issue:41
Gambogic amide, a selective agonist for TrkA receptor that possesses robust neurotrophic activity, prevents neuronal cell death.
AID730912Cmax in CD1 mouse at 20 mg/kg, po by LCMS/MS analysis2013Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1
Garcinia xanthones as orally active antitumor agents.
AID590499Antiproliferative activity against human SMMC7721 cells after 24 hrs by MTT assay2011European journal of medicinal chemistry, Apr, Volume: 46, Issue:4
Studies on chemical modification and biology of a natural product, gambogic acid (III): determination of the essential pharmacophore for biological activity.
AID1216641Drug metabolism in Sprague-Dawley rat feces assessed as 10-OHGA formation at 4 mg/kg, iv measured over 24 hrs by LC-DAD-MS/MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Metabolism of gambogic acid in rats: a rare intestinal metabolic pathway responsible for its final disposition.
AID730927Permeability of the compound at pH 7.4 by PAMPA2013Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1
Garcinia xanthones as orally active antitumor agents.
AID1216648Drug metabolism in rat liver microsomes assessed as glucuronidation product formation at 50 uM preincubated for 10 mins followed by UDPGA addition measured after 2 hrs by LC-MS/MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Metabolism of gambogic acid in rats: a rare intestinal metabolic pathway responsible for its final disposition.
AID716711Inhibition of human recombinant TRX-1 up to 60 mins by insulin reduction assay2012Journal of natural products, Jun-22, Volume: 75, Issue:6
Gambogic acid deactivates cytosolic and mitochondrial thioredoxins by covalent binding to the functional domain.
AID606796Inhibition of Hsp90 in human HeLa cells assessed as Akt degradation at 0.01 to 20 uM by Western blot analysis2011Journal of natural products, May-27, Volume: 74, Issue:5
Gambogic acid, a natural product inhibitor of Hsp90.
AID590683Toxicity in Kunming mouse xenografted with human HepG2 cells assessed as change in body weight at 20 mg/kg, iv administered 24 hrs after tumor implantation one dose per two day for total of four treatment measured after 24 hrs last postdose (Rvb = 20.20 +2011European journal of medicinal chemistry, Apr, Volume: 46, Issue:4
Studies on chemical modification and biology of a natural product, gambogic acid (III): determination of the essential pharmacophore for biological activity.
AID329539Neuroprotective effect in glutamate-induced cell death in rat hippocampal neurons after 30 mins2007Proceedings of the National Academy of Sciences of the United States of America, Oct-09, Volume: 104, Issue:41
Gambogic amide, a selective agonist for TrkA receptor that possesses robust neurotrophic activity, prevents neuronal cell death.
AID1271477Induction of apoptosis in human T98G cells assessed as increase of ROS level at 200 to 400 nM after 10 hrs using DCFH-DA staining by fluorescence microscopic analysis in presence of NAC2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
Gambogic acid induces apoptotic cell death in T98G glioma cells.
AID1207023Permeability of the compound at pH 6.2 by PAMPA2015Bioorganic & medicinal chemistry letters, Jun-15, Volume: 25, Issue:12
Novel natural-product-like caged xanthones with improved druglike properties and in vivo antitumor potency.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID701519Inhibition of GST-tagged recombinant Bcl-XL interaction with biotinylated Bim peptide by ELISA based competitive binding assay2012European journal of medicinal chemistry, Nov, Volume: 57Synthesis and biological activities of polyquinoline derivatives: new Bcl-2 family protein modulators.
AID730917Volume of distribution in CD1 mouse at 5 mg/kg, iv by LCMS/MS analysis2013Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1
Garcinia xanthones as orally active antitumor agents.
AID716707Inhibition of human recombinant TRX-1 by insulin reduction assay2012Journal of natural products, Jun-22, Volume: 75, Issue:6
Gambogic acid deactivates cytosolic and mitochondrial thioredoxins by covalent binding to the functional domain.
AID730916Clearance in CD1 mouse at 5 mg/kg, iv by LCMS/MS analysis2013Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1
Garcinia xanthones as orally active antitumor agents.
AID716717Covalent binding affinity to human recombinant TRX-1 assessed as change in protein configuration at 50 uM by LC-ESIQTOF mass spectrometry2012Journal of natural products, Jun-22, Volume: 75, Issue:6
Gambogic acid deactivates cytosolic and mitochondrial thioredoxins by covalent binding to the functional domain.
AID606950Inhibition of Hsp90-mediated [35S]His-tagged HRI maturation in heme-deficient reticulocyte lysate at 50 uM after 45 mins by SDS-PAGE and autoradiography2011Journal of natural products, May-27, Volume: 74, Issue:5
Gambogic acid, a natural product inhibitor of Hsp90.
AID590498Antiproliferative activity against human BGC823 cells after 24 hrs by MTT assay2011European journal of medicinal chemistry, Apr, Volume: 46, Issue:4
Studies on chemical modification and biology of a natural product, gambogic acid (III): determination of the essential pharmacophore for biological activity.
AID1216634Drug metabolism in Sprague-Dawley rat bile assessed as formation of 10-beta sulfonic gambogic acid at 4 mg/kg, iv measured over 24 hrs by LC-DAD-MS/MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Metabolism of gambogic acid in rats: a rare intestinal metabolic pathway responsible for its final disposition.
AID329571Neuroprotective effect in rat MCAO model assessed as increase in cerebral blood flow at 2 mg/kg after 120 mins of filament withdrawal2007Proceedings of the National Academy of Sciences of the United States of America, Oct-09, Volume: 104, Issue:41
Gambogic amide, a selective agonist for TrkA receptor that possesses robust neurotrophic activity, prevents neuronal cell death.
AID1304321Antibacterial activity against methicillin-resistant Staphylococcus aureus USA300 SF8300 assessed as zone of inhibition at 30 ug after 18 hrs by disk diffusion method2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Caged xanthones: Potent inhibitors of global predominant MRSA USA300.
AID716718Covalent binding affinity to human recombinant TRX-2 assessed as change in protein configuration at 0.05 mM by MALDITOF mass spectrometry2012Journal of natural products, Jun-22, Volume: 75, Issue:6
Gambogic acid deactivates cytosolic and mitochondrial thioredoxins by covalent binding to the functional domain.
AID1271471Induction of apoptosis in human T98G cells assessed as increase of ROS level at 400 nM after 8 hrs using DCFH-DA staining by FACS analysis (Rvb = 2.4%)2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
Gambogic acid induces apoptotic cell death in T98G glioma cells.
AID606793Inhibition of Hsp90 in human MCF7 cells assessed as Her2 degradation after 36 hrs by Western blot analysis2011Journal of natural products, May-27, Volume: 74, Issue:5
Gambogic acid, a natural product inhibitor of Hsp90.
AID730908Antitumor activity against mouse HepS cells allografted in Kunming mouse assessed as inhibition of tumor growth at 100 mg/kg, po qd for 4 days2013Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1
Garcinia xanthones as orally active antitumor agents.
AID328023Growth inhibition of human HCT116 cells after 48 hrs by CellTiter-Glo assay2008Bioorganic & medicinal chemistry, Apr-15, Volume: 16, Issue:8
Synthesis of caged 2,3,3a,7a-tetrahydro-3,6-methanobenzofuran-7(6H)-ones: Evaluating the minimum structure for apoptosis induction by gambogic acid.
AID648761Inhibition of NF-kappaB activation in human A549 cells assessed as inhibition of TNFalpha-induced p65 nuclear translocation treated 4 hrs before TNFalpha stimulation measured after 30 mins by Western blotting2012European journal of medicinal chemistry, May, Volume: 51Studies on gambogic acid (IV): Exploring structure-activity relationship with IκB kinase-beta (IKKβ).
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1543859Potency index, ratio of IC50 for taxol to IC50 for test compound for cytotoxicity against patient derived inflammatory breast cancer cell spheroids assessed as increase in spheroid dissolution incubated for 24 hrs by propidium iodide/Acridine orange stain2019European journal of medicinal chemistry, Apr-15, Volume: 168Synthesis, structure-activity relationship and in vitro pharmacodynamics of A-ring modified caged xanthones in a preclinical model of inflammatory breast cancer.
AID736736Inhibition of human MDM2-p53 interaction expressed in Saccharomyces cerevisiae CG379 assessed as reversal of MDM2-dependent inhibition of p53-induced transcriptional activity at 10 uM after 16 hrs by dual-luciferase reporter gene assay2013Journal of natural products, Apr-26, Volume: 76, Issue:4
Α-mangostin and gambogic acid as potential inhibitors of the p53-MDM2 interaction revealed by a yeast approach.
AID606942Inhibition of Hsp90 interaction with [35S]His-tagged HRI K199R mutant in reticulocyte lysate assessed as coadsorbed Hsp90 at 50 uM after 40 mins by SDS-PAGE and Western blot analysis2011Journal of natural products, May-27, Volume: 74, Issue:5
Gambogic acid, a natural product inhibitor of Hsp90.
AID1632361Antiproliferative activity against human A549 cells assessed as growth inhibition by MTT assay2016Bioorganic & medicinal chemistry, 10-01, Volume: 24, Issue:19
Structure-activity relationship of Garcinia xanthones analogues: Potent Hsp90 inhibitors with cytotoxicity and antiangiogenesis activity.
AID510367Cytotoxicity against human BGC823 cells after 48 hrs by MTT assay2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Studies on chemical modification and biology of a natural product, gambogic acid (II): Synthesis and bioevaluation of gambogellic acid and its derivatives from gambogic acid as antitumor agents.
AID1545897Antiproliferative activity against human U251 cells assessed as reduction in cell viability after 72 hrs by MTT assay2019European journal of medicinal chemistry, Dec-01, Volume: 1831,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
AID1456320Inhibition of recombinant human PTP1B (1 to 322 residues) expressed in Escherichia coli using pNPP as substrate incubated for 10 mins measured for 30 mins by spectrometric analysis
AID1456327Competitive inhibition of recombinant human PTP1B (1 to 322 residues) expressed in Escherichia coli assessed as substrate Vmax at 24.8 uM using pNPP as substrate by Lineweaver-Burk plot analysis (Rvb = 11.95 OD/min)
AID329551Binding affinity to recombinant GST-TrkA2007Proceedings of the National Academy of Sciences of the United States of America, Oct-09, Volume: 104, Issue:41
Gambogic amide, a selective agonist for TrkA receptor that possesses robust neurotrophic activity, prevents neuronal cell death.
AID1456344Ratio of Ki for competitive inhibition of recombinant human PTP1B (1 to 322 residues) expressed in Escherichia coli at 49.6 uM to Ki for non-competitive inhibition of recombinant human PTP1B (1 to 322 residues) expressed in Escherichia coli at 49.6 uM
AID736741Inhibition of human p53 expressed in Saccharomyces cerevisiae CG379 assessed as effect on cell cycle arrest at 1 to 100 uM after 42 hrs2013Journal of natural products, Apr-26, Volume: 76, Issue:4
Α-mangostin and gambogic acid as potential inhibitors of the p53-MDM2 interaction revealed by a yeast approach.
AID1632347Inhibition of 6x-His tagged human recombinant full length Hsp90alpha ATPase preincubated for 0.5 hrs followed by ATP addition measured after 30 mins by HTRF assay2016Bioorganic & medicinal chemistry, 10-01, Volume: 24, Issue:19
Structure-activity relationship of Garcinia xanthones analogues: Potent Hsp90 inhibitors with cytotoxicity and antiangiogenesis activity.
AID1216639Drug metabolism in Sprague-Dawley rat plasma assessed as 10-OHGA formation at 4 mg/kg, iv measured over 4 hrs by LC-DAD-MS/MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Metabolism of gambogic acid in rats: a rare intestinal metabolic pathway responsible for its final disposition.
AID606794Inhibition of Hsp90 in human HeLa cells assessed as Raf degradation at 0.01 to 20 uM after 36 hrs by Western blot analysis2011Journal of natural products, May-27, Volume: 74, Issue:5
Gambogic acid, a natural product inhibitor of Hsp90.
AID1271475Induction of apoptosis in human T98G cells assessed as increase of ROS level at 200 nM after 8 hrs using DCFH-DA staining by FACS analysis in presence of NAC (Rvb = 2.4%)2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
Gambogic acid induces apoptotic cell death in T98G glioma cells.
AID606943Inhibition of Hsp70 interaction with [35S]His-tagged HRI K199R mutant in reticulocyte lysate assessed as coadsorbed Hsp70 at 50 uM after 40 mins by SDS-PAGE and Western blot analysis2011Journal of natural products, May-27, Volume: 74, Issue:5
Gambogic acid, a natural product inhibitor of Hsp90.
AID606863Inhibition of Hsp90 in human SKBR3 cells assessed as induction of Hsp70 expression after 36 hrs by Western blot analysis2011Journal of natural products, May-27, Volume: 74, Issue:5
Gambogic acid, a natural product inhibitor of Hsp90.
AID648824Antiproliferative activity against human A549 cells after 24 hrs by MTT assay2012European journal of medicinal chemistry, May, Volume: 51Studies on gambogic acid (IV): Exploring structure-activity relationship with IκB kinase-beta (IKKβ).
AID329553Binding affinity to recombinant GST-TrkC2007Proceedings of the National Academy of Sciences of the United States of America, Oct-09, Volume: 104, Issue:41
Gambogic amide, a selective agonist for TrkA receptor that possesses robust neurotrophic activity, prevents neuronal cell death.
AID606789Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth after 72 hrs by cell titer 96 assay2011Journal of natural products, May-27, Volume: 74, Issue:5
Gambogic acid, a natural product inhibitor of Hsp90.
AID473882Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay2010Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8
Spectacular modification of Gambogic acid on microwave irradiation in methanol: isolation and structure identification of two products with potent anti-tumor activity.
AID1632365Antiproliferative activity against human HepG2 cells assessed as growth inhibition by MTT assay2016Bioorganic & medicinal chemistry, 10-01, Volume: 24, Issue:19
Structure-activity relationship of Garcinia xanthones analogues: Potent Hsp90 inhibitors with cytotoxicity and antiangiogenesis activity.
AID716716Covalent binding affinity to human recombinant TRX-2 assessed as change in protein configuration at 20 uM by LC-ESIQTOF mass spectrometry2012Journal of natural products, Jun-22, Volume: 75, Issue:6
Gambogic acid deactivates cytosolic and mitochondrial thioredoxins by covalent binding to the functional domain.
AID1304337Bactericidal activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 after 18 to 20 hrs2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Caged xanthones: Potent inhibitors of global predominant MRSA USA300.
AID662808Cytotoxicity against human KBVIN cells by MTT assay2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Design and synthesis of gambogic acid analogs as potent cytotoxic and anti-inflammatory agents.
AID1216631Drug metabolism in PBS buffer assessed as formation of 10-glutathionyl gambogic acid at 50 uM preincubated for 10 mins followed by NADPH addition measured after 2 hrs in presence of GSH and absence of liver microsomes2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Metabolism of gambogic acid in rats: a rare intestinal metabolic pathway responsible for its final disposition.
AID730919Mean residence time in CD1 mouse at 5 mg/kg, iv by LCMS/MS analysis2013Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1
Garcinia xanthones as orally active antitumor agents.
AID730909Oral bioavailability in CD1 mouse at 20 mg/kg by LCMS/MS analysis2013Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1
Garcinia xanthones as orally active antitumor agents.
AID1216627Retention time of the compound in Sprague-Dawley rat bile at 4 mg/kg, iv measured over 24 hrs by LC-DAD-MS/MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Metabolism of gambogic acid in rats: a rare intestinal metabolic pathway responsible for its final disposition.
AID606958Binding affinity to human Hsp90 N-terminal domain (1 to 241) expressed in insect Sf9 cells by SPR analysis2011Journal of natural products, May-27, Volume: 74, Issue:5
Gambogic acid, a natural product inhibitor of Hsp90.
AID662809Cytotoxicity against human A549 cells by MTT assay2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Design and synthesis of gambogic acid analogs as potent cytotoxic and anti-inflammatory agents.
AID1216655Drug level in Sprague-Dawley rat urine at 4 mg/kg, iv measured over 24 hrs by LC-DAD-MS/MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Metabolism of gambogic acid in rats: a rare intestinal metabolic pathway responsible for its final disposition.
AID606862Inhibition of Hsp90 in human MCF7 cells assessed as induction of Hsp70 expression after 36 hrs by Western blot analysis2011Journal of natural products, May-27, Volume: 74, Issue:5
Gambogic acid, a natural product inhibitor of Hsp90.
AID730932Cytotoxicity against human HepG2 cells assessed as cell viability after 24 hrs by MTT assay2013Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1
Garcinia xanthones as orally active antitumor agents.
AID606861Inhibition of Hsp90 in human SKBR3 cells assessed as Raf degradation after 36 hrs by Western blot analysis2011Journal of natural products, May-27, Volume: 74, Issue:5
Gambogic acid, a natural product inhibitor of Hsp90.
AID1216653Drug metabolism in Sprague-Dawley rat gut assessed as formation of 10-alpha sulfonic gambogic acid at 4 mg/kg, iv2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Metabolism of gambogic acid in rats: a rare intestinal metabolic pathway responsible for its final disposition.
AID1216645Drug metabolism in Sprague-Dawley rat feces assessed as formation of glucuronidation product at 4 mg/kg, iv measured over 24 hrs by LC-DAD-MS/MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Metabolism of gambogic acid in rats: a rare intestinal metabolic pathway responsible for its final disposition.
AID1271461Induction of apoptosis in human T98G cells assessed as late-stage apoptotic cells at 400 nM after 24 hrs using annexin V/propidium iodide staining by FACS analysis2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
Gambogic acid induces apoptotic cell death in T98G glioma cells.
AID730930Cytotoxicity against human U251 cells assessed as cell viability after 24 hrs by MTT assay2013Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1
Garcinia xanthones as orally active antitumor agents.
AID1216644Drug metabolism in PBS buffer assessed as 10-OHGA formation at 50 uM preincubated for 10 mins followed by NADPH addition measured after 1 hr by LC-DAD-MS/MS analysis in absence of liver microsomes2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Metabolism of gambogic acid in rats: a rare intestinal metabolic pathway responsible for its final disposition.
AID329552Binding affinity to recombinant GST-TrkB2007Proceedings of the National Academy of Sciences of the United States of America, Oct-09, Volume: 104, Issue:41
Gambogic amide, a selective agonist for TrkA receptor that possesses robust neurotrophic activity, prevents neuronal cell death.
AID1456321Potency index, ratio of ursolic acid IC50 to compound IC50 for recombinant human PTP1B (1 to 322 residues) expressed in Escherichia coli
AID606996Binding affinity to human Hsp90 C-terminal domain (531 to 732) expressed in Escherichia coli DE-3cstar cells by SPR analysis2011Journal of natural products, May-27, Volume: 74, Issue:5
Gambogic acid, a natural product inhibitor of Hsp90.
AID716706Covalent binding affinity to human recombinant TRX-1 C assessed as modification in C62/C69/C73 residues by LC-MS/MS analysis2012Journal of natural products, Jun-22, Volume: 75, Issue:6
Gambogic acid deactivates cytosolic and mitochondrial thioredoxins by covalent binding to the functional domain.
AID1456329Competitive inhibition of recombinant human PTP1B (1 to 322 residues) expressed in Escherichia coli assessed as substrate Km at 12.4 uM using pNPP as substrate by Lineweaver-Burk plot analysis (Rvb = 0.95 mM)
AID1304338Bactericidal activity against methicillin-resistant Staphylococcus aureus USA300 SF8300 after 18 to 20 hrs2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Caged xanthones: Potent inhibitors of global predominant MRSA USA300.
AID701518Inhibition of GST-tagged recombinant Bcl2 interaction with biotinylated Bim peptide by ELISA based competitive binding assay2012European journal of medicinal chemistry, Nov, Volume: 57Synthesis and biological activities of polyquinoline derivatives: new Bcl-2 family protein modulators.
AID1304326Cytotoxicity against human A549 cells assessed as reduction in cell viability after 24 to 48 hrs by Presto Blue assay2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Caged xanthones: Potent inhibitors of global predominant MRSA USA300.
AID716719Covalent binding affinity to human recombinant TRX-1 assessed as change in protein configuration at 0.1 mM by MALDITOF mass spectrometry2012Journal of natural products, Jun-22, Volume: 75, Issue:6
Gambogic acid deactivates cytosolic and mitochondrial thioredoxins by covalent binding to the functional domain.
AID1594008Induction of apoptosis in human HCT116 cells assessed as early apoptotic cells level at 1 uM incubated for 48 hrs by Annexin V-FITC and propidium iodide staining based flow cytometry2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Design, synthesis and antitumour and anti-angiogenesis evaluation of 22 moscatilin derivatives.
AID510368Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Studies on chemical modification and biology of a natural product, gambogic acid (II): Synthesis and bioevaluation of gambogellic acid and its derivatives from gambogic acid as antitumor agents.
AID419842Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay2009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
Studies on chemical structure modification and biology of a natural product, gambogic acid (I): Synthesis and biological evaluation of oxidized analogues of gambogic acid.
AID1216615Drug metabolism in PBS buffer assessed as 9,10-epoxyl-gambogic acid formation at 50 uM preincubated for 10 mins followed by NADPH addition measured after 1 hr by LC-MS/MS analysis in absence of liver microsomes2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Metabolism of gambogic acid in rats: a rare intestinal metabolic pathway responsible for its final disposition.
AID1271457Induction of apoptosis in human T98G cells assessed as necrotic cells at 200 nM after 24 hrs using annexin V/propidium iodide staining by FACS analysis2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
Gambogic acid induces apoptotic cell death in T98G glioma cells.
AID1271469Induction of apoptosis in human T98G cells assessed as increase of cytochrome-c protein level at 200 to 400 nM after 10 to 24 hrs by Western blot analysis2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
Gambogic acid induces apoptotic cell death in T98G glioma cells.
AID329536Suppression of staurosporine-initiated apoptosis in mouse SN56 cells at 0.5 uM2007Proceedings of the National Academy of Sciences of the United States of America, Oct-09, Volume: 104, Issue:41
Gambogic amide, a selective agonist for TrkA receptor that possesses robust neurotrophic activity, prevents neuronal cell death.
AID730929Partition coefficient, log D of the compound at pH 7.42013Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1
Garcinia xanthones as orally active antitumor agents.
AID1271456Antiproliferative activity against human T98G cells after 24 hrs by EZ-Tox assay2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
Gambogic acid induces apoptotic cell death in T98G glioma cells.
AID1271472Induction of apoptosis in human T98G cells assessed as increase of ROS level at 400 nM after 8 hrs using DCFH-DA staining by FACS analysis in presence of NAC (Rvb = 2.4%)2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
Gambogic acid induces apoptotic cell death in T98G glioma cells.
AID1271480Induction of apoptosis in human T98G cells assessed as decrease in cell viability at 400 nM after 24 hrs using propidium iodide /Hoechst staining by FACS analysis in presence of NAC (Rvb = 2.9%)2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
Gambogic acid induces apoptotic cell death in T98G glioma cells.
AID716710Inhibition of human recombinant TRX-2 up to 60 mins by insulin reduction assay2012Journal of natural products, Jun-22, Volume: 75, Issue:6
Gambogic acid deactivates cytosolic and mitochondrial thioredoxins by covalent binding to the functional domain.
AID1216635Drug metabolism in Sprague-Dawley rat feces assessed as formation of 9,10-epoxyl-gambogic acid at 4 mg/kg, iv measured over 24 hrs by LC-DAD-MS/MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Metabolism of gambogic acid in rats: a rare intestinal metabolic pathway responsible for its final disposition.
AID328019Induction of apoptosis in human T47D cells assessed as caspase 3 activation after 24 hrs2008Bioorganic & medicinal chemistry, Apr-15, Volume: 16, Issue:8
Synthesis of caged 2,3,3a,7a-tetrahydro-3,6-methanobenzofuran-7(6H)-ones: Evaluating the minimum structure for apoptosis induction by gambogic acid.
AID1216647Drug metabolism assessed as formation of 10-OHGA in presence of NADPH and oxygen2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Metabolism of gambogic acid in rats: a rare intestinal metabolic pathway responsible for its final disposition.
AID1216622Drug metabolism in intestine (unknown origin) assessed as 10-beta sulfonic gambogic acid formation2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Metabolism of gambogic acid in rats: a rare intestinal metabolic pathway responsible for its final disposition.
AID1207019Cytotoxicity against human A549 cells assessed as growth inhibition after 24 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Jun-15, Volume: 25, Issue:12
Novel natural-product-like caged xanthones with improved druglike properties and in vivo antitumor potency.
AID638230Cytotoxicity against human QGY7701 cells after 72 hrs by MTT assay2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Synthesis and biological evaluation of novel derivatives of gambogic acid as anti-hepatocellular carcinoma agents.
AID1456325Competitive inhibition of recombinant human PTP1B (1 to 322 residues) expressed in Escherichia coli assessed as substrate Vmax at 12.4 uM using pNPP as substrate by Lineweaver-Burk plot analysis (Rvb = 11.95 OD/min)
AID1545894Antiproliferative activity against human A549/CDDP cells assessed as reduction in cell viability after 72 hrs by MTT assay2019European journal of medicinal chemistry, Dec-01, Volume: 1831,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
AID1216651Drug metabolism in rat liver microsomes assessed as glucuronidation product formation at 50 uM preincubated for 10 mins followed by UDPGA addition for 2 hrs measured 2 hrs post NaOH treatment by LC-MS/MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Metabolism of gambogic acid in rats: a rare intestinal metabolic pathway responsible for its final disposition.
AID701525Induction of apoptosis in human BP3 cells at 5 uM incubated for 24 hrs by Annexin V and propidium iodide staining based FACS method2012European journal of medicinal chemistry, Nov, Volume: 57Synthesis and biological activities of polyquinoline derivatives: new Bcl-2 family protein modulators.
AID329562Induction of Akt phosphorylation in rat primary hippocampal neurons2007Proceedings of the National Academy of Sciences of the United States of America, Oct-09, Volume: 104, Issue:41
Gambogic amide, a selective agonist for TrkA receptor that possesses robust neurotrophic activity, prevents neuronal cell death.
AID510369Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Studies on chemical modification and biology of a natural product, gambogic acid (II): Synthesis and bioevaluation of gambogellic acid and its derivatives from gambogic acid as antitumor agents.
AID329541Induction of TrkA phosphorylation in rat hippocampal neurons at 0.5 uM after 30 mins2007Proceedings of the National Academy of Sciences of the United States of America, Oct-09, Volume: 104, Issue:41
Gambogic amide, a selective agonist for TrkA receptor that possesses robust neurotrophic activity, prevents neuronal cell death.
AID1271460Induction of apoptosis in human T98G cells assessed as necrotic cells at 400 nM after 24 hrs using annexin V/propidium iodide staining by FACS analysis2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
Gambogic acid induces apoptotic cell death in T98G glioma cells.
AID736734Inhibition of human p53 R280K mutant expressed in Saccharomyces cerevisiae CG379 assessed as effect on cell growth at 10 uM after 31 hrs2013Journal of natural products, Apr-26, Volume: 76, Issue:4
Α-mangostin and gambogic acid as potential inhibitors of the p53-MDM2 interaction revealed by a yeast approach.
AID701523Induction of apoptosis in human RS4:11 cells at 5 uM incubated for 24 hrs by Annexin V and propidium iodide staining based FACS method2012European journal of medicinal chemistry, Nov, Volume: 57Synthesis and biological activities of polyquinoline derivatives: new Bcl-2 family protein modulators.
AID1207022Permeability of the compound at pH 5 by PAMPA2015Bioorganic & medicinal chemistry letters, Jun-15, Volume: 25, Issue:12
Novel natural-product-like caged xanthones with improved druglike properties and in vivo antitumor potency.
AID1632360Antiproliferative activity against human MCF7 cells assessed as growth inhibition by MTT assay2016Bioorganic & medicinal chemistry, 10-01, Volume: 24, Issue:19
Structure-activity relationship of Garcinia xanthones analogues: Potent Hsp90 inhibitors with cytotoxicity and antiangiogenesis activity.
AID329554Induction of ERK1 phosphorylation2007Proceedings of the National Academy of Sciences of the United States of America, Oct-09, Volume: 104, Issue:41
Gambogic amide, a selective agonist for TrkA receptor that possesses robust neurotrophic activity, prevents neuronal cell death.
AID328020Induction of apoptosis in human HCT116 cells assessed as caspase 3 activation after 24 hrs2008Bioorganic & medicinal chemistry, Apr-15, Volume: 16, Issue:8
Synthesis of caged 2,3,3a,7a-tetrahydro-3,6-methanobenzofuran-7(6H)-ones: Evaluating the minimum structure for apoptosis induction by gambogic acid.
AID1271478Induction of apoptosis in human T98G cells assessed as decrease in cell viability at 400 nM after 24 hrs using propidium iodide /Hoechst staining by FACS analysis (Rvb = 2.9%)2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
Gambogic acid induces apoptotic cell death in T98G glioma cells.
AID701520Induction of cell death in mouse MEF cells containing Bax/Bak double knock out at 1 uM by Annexin V and propidium iodide staining based FACS method2012European journal of medicinal chemistry, Nov, Volume: 57Synthesis and biological activities of polyquinoline derivatives: new Bcl-2 family protein modulators.
AID606797Inhibition of Hsp90 in human MCF7 cells assessed as induction of Hsp90 expression after 36 hrs by Western blot analysis2011Journal of natural products, May-27, Volume: 74, Issue:5
Gambogic acid, a natural product inhibitor of Hsp90.
AID1216654Drug metabolism in Sprague-Dawley rat gut assessed as formation of 10-beta sulfonic gambogic acid at 4 mg/kg, iv2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Metabolism of gambogic acid in rats: a rare intestinal metabolic pathway responsible for its final disposition.
AID1594001Antiproliferative activity against human HCT116 cells incubated for 72 hrs by MTT assay2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Design, synthesis and antitumour and anti-angiogenesis evaluation of 22 moscatilin derivatives.
AID606791Antiproliferative activity against human SKBR3 cells assessed as inhibition of cell growth after 72 hrs by cell titer 96 assay2011Journal of natural products, May-27, Volume: 74, Issue:5
Gambogic acid, a natural product inhibitor of Hsp90.
AID730928Intrinsic solubility of the compound2013Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1
Garcinia xanthones as orally active antitumor agents.
AID736739Inhibition of human MDM2 expressed in Saccharomyces cerevisiae CG379 assessed as effect on cell cycle arrest at 1 to 100 uM after 42 hrs2013Journal of natural products, Apr-26, Volume: 76, Issue:4
Α-mangostin and gambogic acid as potential inhibitors of the p53-MDM2 interaction revealed by a yeast approach.
AID473880Cytotoxicity against human BGC803 cells after 48 hrs by MTT assay2010Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8
Spectacular modification of Gambogic acid on microwave irradiation in methanol: isolation and structure identification of two products with potent anti-tumor activity.
AID1456342Inhibition of recombinant human PTP1B (1 to 322 residues) expressed in Escherichia coli assessed as enzyme-substrate-inhibitor complex using pNPP as substrate preincubated for 60 mins followed by substrate addition measured at 30 secs interval for 10 mins
AID1456324Inhibition of recombinant human PTP1B (1 to 322 residues) expressed in Escherichia coli using pNPP as substrate preincubated for 60 mins followed by substrate addition measured for 10 mins by UV-spectrophotmetric method
AID1169352Cytotoxicity against human HepG2 cells2014Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22
Antimalarial activity of abietane ferruginol analogues possessing a phthalimide group.
AID473879Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay2010Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8
Spectacular modification of Gambogic acid on microwave irradiation in methanol: isolation and structure identification of two products with potent anti-tumor activity.
AID716708Inhibition of human recombinant TRX-2 by insulin reduction assay2012Journal of natural products, Jun-22, Volume: 75, Issue:6
Gambogic acid deactivates cytosolic and mitochondrial thioredoxins by covalent binding to the functional domain.
AID638231Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Synthesis and biological evaluation of novel derivatives of gambogic acid as anti-hepatocellular carcinoma agents.
AID1456326Time dependent inhibition of recombinant human PTP1B (1 to 322 residues) expressed in Escherichia coli at 0.47 uM using pNPP as substrate preincubated with enzyme for 60 mins by UV-spectrophotometric method
AID1410127Growth inhibition of human K562 cells measured after 3 days by trypan blue assay2018Journal of natural products, 04-27, Volume: 81, Issue:4
Bioassay- and Chemistry-Guided Isolation of Scalemic Caged Prenylxanthones from the Leaves of Garcinia bracteata.
AID606788Inhibition of Hsp90-dependent refolding of luciferase in reticulocyte lysate by microplate reader2011Journal of natural products, May-27, Volume: 74, Issue:5
Gambogic acid, a natural product inhibitor of Hsp90.
AID1593999Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Design, synthesis and antitumour and anti-angiogenesis evaluation of 22 moscatilin derivatives.
AID328021Induction of apoptosis in human SNU398 cells assessed as caspase 3 activation after 24 hrs2008Bioorganic & medicinal chemistry, Apr-15, Volume: 16, Issue:8
Synthesis of caged 2,3,3a,7a-tetrahydro-3,6-methanobenzofuran-7(6H)-ones: Evaluating the minimum structure for apoptosis induction by gambogic acid.
AID730922Antitumor activity against mouse HepS cells allografted in Kunming mouse assessed as inhibition of tumor growth at 10 mg/kg, iv bid administered 2 days once for 4 times2013Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1
Garcinia xanthones as orally active antitumor agents.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1271459Induction of apoptosis in human T98G cells assessed as early-stage apoptotic cells at 200 nM after 24 hrs using annexin V/propidium iodide staining by FACS analysis2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
Gambogic acid induces apoptotic cell death in T98G glioma cells.
AID606956Effect on [35S]His-tagged HRI stability in heme-deficient reticulocyte lysate assessed as loss of [35S]His-tagged HRI at 50 uM after 45 mins by SDS-PAGE and autoradiography2011Journal of natural products, May-27, Volume: 74, Issue:5
Gambogic acid, a natural product inhibitor of Hsp90.
AID1169354Cytotoxicity against human BJ cells2014Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22
Antimalarial activity of abietane ferruginol analogues possessing a phthalimide group.
AID473881Cytotoxicity against human SGC7901 cells after 48 hrs by MTT assay2010Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8
Spectacular modification of Gambogic acid on microwave irradiation in methanol: isolation and structure identification of two products with potent anti-tumor activity.
AID1632362Antiproliferative activity against human SK-BR-3 cells assessed as growth inhibition by MTT assay2016Bioorganic & medicinal chemistry, 10-01, Volume: 24, Issue:19
Structure-activity relationship of Garcinia xanthones analogues: Potent Hsp90 inhibitors with cytotoxicity and antiangiogenesis activity.
AID1216643Drug metabolism in PBS buffer assessed as 10-OHGA formation at 50 uM preincubated for 10 mins by LC-DAD-MS/MS analysis in absence of liver microsomes and NADPH2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Metabolism of gambogic acid in rats: a rare intestinal metabolic pathway responsible for its final disposition.
AID1216629Drug metabolism in Sprague-Dawley rat bile assessed as 10-alpha sulfonic gambogic acid formation of at 4 mg/kg, iv measured over 24 hrs by LC-DAD-MS/MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Metabolism of gambogic acid in rats: a rare intestinal metabolic pathway responsible for its final disposition.
AID1271458Induction of apoptosis in human T98G cells assessed as late-stage apoptotic cells at 200 nM after 24 hrs using annexin V/propidium iodide staining by FACS analysis2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
Gambogic acid induces apoptotic cell death in T98G glioma cells.
AID1304327Cytotoxicity against human HEK293 cells assessed as reduction in cell viability after 24 to 48 hrs by trypan blue dye based fluorescence assay2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Caged xanthones: Potent inhibitors of global predominant MRSA USA300.
AID716705Covalent binding affinity to human recombinant TRX-2 C assessed as modification in C31/C34 residues by LC-MS/MS analysis2012Journal of natural products, Jun-22, Volume: 75, Issue:6
Gambogic acid deactivates cytosolic and mitochondrial thioredoxins by covalent binding to the functional domain.
AID1216646Drug metabolism assessed as formation of 10-OHGA in presence of NADPH and absence of oxygen2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Metabolism of gambogic acid in rats: a rare intestinal metabolic pathway responsible for its final disposition.
AID329565Induction of neurite outgrowth in rat PC12 cells at 0.5 uM after 5 days2007Proceedings of the National Academy of Sciences of the United States of America, Oct-09, Volume: 104, Issue:41
Gambogic amide, a selective agonist for TrkA receptor that possesses robust neurotrophic activity, prevents neuronal cell death.
AID648823Inhibition of IKK-beta using TMB substrate after 15 mins by spectrophotometer analysis2012European journal of medicinal chemistry, May, Volume: 51Studies on gambogic acid (IV): Exploring structure-activity relationship with IκB kinase-beta (IKKβ).
AID1216625Drug level in Sprague-Dawley rat plasma at 4 mg/kg, iv measured over 4 hrs by LC-DAD-MS/MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Metabolism of gambogic acid in rats: a rare intestinal metabolic pathway responsible for its final disposition.
AID606865Inhibition of Hsp90 in human SKBR3 cells assessed as Akt degradation after 36 hrs by Western blot analysis2011Journal of natural products, May-27, Volume: 74, Issue:5
Gambogic acid, a natural product inhibitor of Hsp90.
AID1271470Induction of apoptosis in human T98G cells assessed as decrease of Bcl-2 level at 200 to 400 nM after 10 to 24 hrs by Western blot analysis2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
Gambogic acid induces apoptotic cell death in T98G glioma cells.
AID1207018Cytotoxicity against human HepG2 cells assessed as growth inhibition after 24 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Jun-15, Volume: 25, Issue:12
Novel natural-product-like caged xanthones with improved druglike properties and in vivo antitumor potency.
AID1216620Drug excretion in Sprague-Dawley rat feces at 2 mg/kg, iv measured within 48 hrs2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Metabolism of gambogic acid in rats: a rare intestinal metabolic pathway responsible for its final disposition.
AID1271481Induction of apoptosis in human T98G cells assessed as decrease in cell viability after 24 hrs using propidium iodide /Hoechst staining by FACS analysis2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
Gambogic acid induces apoptotic cell death in T98G glioma cells.
AID328024Growth inhibition of human SNU398 cells after 48 hrs by CellTiter-Glo assay2008Bioorganic & medicinal chemistry, Apr-15, Volume: 16, Issue:8
Synthesis of caged 2,3,3a,7a-tetrahydro-3,6-methanobenzofuran-7(6H)-ones: Evaluating the minimum structure for apoptosis induction by gambogic acid.
AID730910AUC in CD1 mouse at 20 mg/kg, po by LCMS/MS analysis2013Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1
Garcinia xanthones as orally active antitumor agents.
AID1216624Drug metabolism in intestine (unknown origin) assessed as 10-alpha sulfonic gambogic acid formation2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Metabolism of gambogic acid in rats: a rare intestinal metabolic pathway responsible for its final disposition.
AID701516Inhibition of GST-tagged recombinant Bfl1 interaction with biotinylated Bim peptide by ELISA based competitive binding assay2012European journal of medicinal chemistry, Nov, Volume: 57Synthesis and biological activities of polyquinoline derivatives: new Bcl-2 family protein modulators.
AID1169355Cytotoxicity against HEK293 cells2014Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22
Antimalarial activity of abietane ferruginol analogues possessing a phthalimide group.
AID1271473Induction of apoptosis in human T98G cells assessed as decrease in cell viability at 200 nM after 24 hrs using propidium iodide /Hoechst staining by FACS analysis (Rvb = 2.9%)2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
Gambogic acid induces apoptotic cell death in T98G glioma cells.
AID328022Growth inhibition of human T47D cells after 48 hrs by CellTiter-Glo assay2008Bioorganic & medicinal chemistry, Apr-15, Volume: 16, Issue:8
Synthesis of caged 2,3,3a,7a-tetrahydro-3,6-methanobenzofuran-7(6H)-ones: Evaluating the minimum structure for apoptosis induction by gambogic acid.
AID716709Inhibition of TRX1 in human SMMC-7221 cells after 2 hrs by insulin reduction assay2012Journal of natural products, Jun-22, Volume: 75, Issue:6
Gambogic acid deactivates cytosolic and mitochondrial thioredoxins by covalent binding to the functional domain.
AID1410126Growth inhibition of human HL60 cells measured after 3 days by trypan blue assay2018Journal of natural products, 04-27, Volume: 81, Issue:4
Bioassay- and Chemistry-Guided Isolation of Scalemic Caged Prenylxanthones from the Leaves of Garcinia bracteata.
AID638229Cytotoxicity against human Bel7404 cells after 72 hrs by MTT assay2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Synthesis and biological evaluation of novel derivatives of gambogic acid as anti-hepatocellular carcinoma agents.
AID606860Inhibition of Hsp90 in human MCF7 cells assessed as Raf degradation after 36 hrs by Western blot analysis2011Journal of natural products, May-27, Volume: 74, Issue:5
Gambogic acid, a natural product inhibitor of Hsp90.
AID1594144Inhibition of Escherichia coli GroEL expressed in Escherichia coliDH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured soluble pig heart MDH refolding by measuring MDH enzyme acti2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID736738Inhibition of human MDM2-p53 interaction expressed in Saccharomyces cerevisiae CG379 assessed as reversal of MDM2-dependent inhibition of p53-induced growth inhibition at 10 uM after 42 hrs2013Journal of natural products, Apr-26, Volume: 76, Issue:4
Α-mangostin and gambogic acid as potential inhibitors of the p53-MDM2 interaction revealed by a yeast approach.
AID701517Inhibition of GST-tagged recombinant Mcl1 interaction with biotinylated Bim peptide by ELISA based competitive binding assay2012European journal of medicinal chemistry, Nov, Volume: 57Synthesis and biological activities of polyquinoline derivatives: new Bcl-2 family protein modulators.
AID736740Inhibition of human p53 expressed in Saccharomyces cerevisiae CG379 assessed as effect on cell growth at 1 to 100 uM after 42 hrs2013Journal of natural products, Apr-26, Volume: 76, Issue:4
Α-mangostin and gambogic acid as potential inhibitors of the p53-MDM2 interaction revealed by a yeast approach.
AID1545892Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay2019European journal of medicinal chemistry, Dec-01, Volume: 1831,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
AID1545896Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay2019European journal of medicinal chemistry, Dec-01, Volume: 1831,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
AID1216630Drug metabolism in rat liver microsomes assessed as formation of 10-glutathionyl gambogic acid at 50 uM preincubated for 10 mins followed by NADPH addition measured after 2 hrs in presence of GSH2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Metabolism of gambogic acid in rats: a rare intestinal metabolic pathway responsible for its final disposition.
AID1169349Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 assessed as inhibition of parasite growth after 72 hrs by cell based assay2014Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22
Antimalarial activity of abietane ferruginol analogues possessing a phthalimide group.
AID648822Inhibition of TNF-alpha-induced IkappaBalpha phosphorylation in human A549 cells at 4 to 8 uM treated 4 hrs before TNFalpha stimulation measured after 30 mins by Western blotting2012European journal of medicinal chemistry, May, Volume: 51Studies on gambogic acid (IV): Exploring structure-activity relationship with IκB kinase-beta (IKKβ).
AID638228Cytotoxicity against human SMMC7721 cells after 72 hrs by MTT assay2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Synthesis and biological evaluation of novel derivatives of gambogic acid as anti-hepatocellular carcinoma agents.
AID1169356Antimalarial activity against chloroquine-resistant Plasmodium falciparum K1 assessed as inhibition of parasite growth after 72 hrs by cell based assay2014Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22
Antimalarial activity of abietane ferruginol analogues possessing a phthalimide group.
AID1456330Competitive inhibition of recombinant human PTP1B (1 to 322 residues) expressed in Escherichia coli assessed as substrate Km at 24.8 uM using pNPP as substrate by Lineweaver-Burk plot analysis (Rvb = 0.95 mM)
AID662810Cytotoxicity against human DU145 cells by MTT assay2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Design and synthesis of gambogic acid analogs as potent cytotoxic and anti-inflammatory agents.
AID1632363Antiproliferative activity against human HT-29 cells assessed as growth inhibition by MTT assay2016Bioorganic & medicinal chemistry, 10-01, Volume: 24, Issue:19
Structure-activity relationship of Garcinia xanthones analogues: Potent Hsp90 inhibitors with cytotoxicity and antiangiogenesis activity.
AID1545893Antiproliferative activity against human A549/TR cells assessed as reduction in cell viability after 72 hrs by MTT assay2019European journal of medicinal chemistry, Dec-01, Volume: 1831,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
AID419838Cytotoxicity against human A549 cells after 48 hrs by MTT assay2009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
Studies on chemical structure modification and biology of a natural product, gambogic acid (I): Synthesis and biological evaluation of oxidized analogues of gambogic acid.
AID1377215Inhibition of RGS17 (unknown origin) GAP activity in presence of GTP by malachite green dye based assay2017Journal of natural products, 07-28, Volume: 80, Issue:7
Natural Products Discovered in a High-Throughput Screen Identified as Inhibitors of RGS17 and as Cytostatic and Cytotoxic Agents for Lung and Prostate Cancer Cell Lines.
AID419840Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay2009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
Studies on chemical structure modification and biology of a natural product, gambogic acid (I): Synthesis and biological evaluation of oxidized analogues of gambogic acid.
AID329537Suppression of staurosporine-initiated apoptosis in human T17 cells at 0.5 uM2007Proceedings of the National Academy of Sciences of the United States of America, Oct-09, Volume: 104, Issue:41
Gambogic amide, a selective agonist for TrkA receptor that possesses robust neurotrophic activity, prevents neuronal cell death.
AID1594011Induction of apoptosis in human HCT116 cells assessed as late apoptotic cells level at 1 uM incubated for 48 hrs by Annexin V-FITC and propidium iodide staining based flow cytometry2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Design, synthesis and antitumour and anti-angiogenesis evaluation of 22 moscatilin derivatives.
AID1216636Drug metabolism in rat liver microsomes assessed as CYP450-mediated 9,10-epoxyl-gambogic acid formation at 50 uM preincubated for 10 mins followed by NADPH addition measured after 1 hr by LC-DAD-MS/MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Metabolism of gambogic acid in rats: a rare intestinal metabolic pathway responsible for its final disposition.
AID1557475Antitumour activity against human MDA-MB-231 cells xenografted in Nu/Nu mouse at 10 mg/kg, iv for 6 times at 2 days interval2019Journal of natural products, 03-22, Volume: 82, Issue:3
Potential Anticancer Agents Characterized from Selected Tropical Plants.
AID1456319Ratio of Ki for competitive inhibition of recombinant human PTP1B (1 to 322 residues) expressed in Escherichia coli at 12.4 uM to Ki for non-competitive inhibition of recombinant human PTP1B (1 to 322 residues) expressed in Escherichia coli at 12.4 uM
AID1304324Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 assessed as growth inhibition after 18 to 20 hrs by microdilution assay2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Caged xanthones: Potent inhibitors of global predominant MRSA USA300.
AID730931Cytotoxicity against human A549 cells assessed as cell viability after 24 hrs by MTT assay2013Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1
Garcinia xanthones as orally active antitumor agents.
AID1545895Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay2019European journal of medicinal chemistry, Dec-01, Volume: 1831,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
AID510365Cytotoxicity against human A549 cells after 48 hrs by MTT assay2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Studies on chemical modification and biology of a natural product, gambogic acid (II): Synthesis and bioevaluation of gambogellic acid and its derivatives from gambogic acid as antitumor agents.
AID638226Aqueous solubility of the compound2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Synthesis and biological evaluation of novel derivatives of gambogic acid as anti-hepatocellular carcinoma agents.
AID590679Antitumor activity against human HepG2 cells xenografted in Kunming mouse assessed as tumor growth inhibition at 20 mg/kg, iv administered 24 hrs after tumor implantation one dose per two day for total of four treatment measured after 24 hrs last postdose2011European journal of medicinal chemistry, Apr, Volume: 46, Issue:4
Studies on chemical modification and biology of a natural product, gambogic acid (III): determination of the essential pharmacophore for biological activity.
AID1216650Drug metabolism in rat liver microsomes assessed as glucuronidation product formation at 50 uM preincubated for 10 mins followed by UDPGA addition for 2 hrs measured 1 hr post beta-glucuronidase treatment by LC-MS/MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Metabolism of gambogic acid in rats: a rare intestinal metabolic pathway responsible for its final disposition.
AID1271466Induction of apoptosis in human T98G cells assessed as increase of cleaved PARP level at 200 to 400 nM after 10 to 24 hrs by Western blot analysis2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
Gambogic acid induces apoptotic cell death in T98G glioma cells.
AID1456332Inhibition of recombinant human PTP1B (1 to 322 residues) expressed in Escherichia coli using pNPP as substrate preincubated for 60 mins followed by substrate addition measured at 30 secs interval for 10 mins by UV-spectrophotmetric method
AID1216656Drug metabolism in rat liver microsomes assessed as 9,10-epoxyl-gambogic acid formation at 50 uM preincubated for 10 mins by LC-MS/MS analysis in absence of NADPH2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Metabolism of gambogic acid in rats: a rare intestinal metabolic pathway responsible for its final disposition.
AID1216623Drug metabolism in rat liver microsomes assessed as SULT-mediated sulfonation2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Metabolism of gambogic acid in rats: a rare intestinal metabolic pathway responsible for its final disposition.
AID701524Induction of apoptosis in human IM9 cells at 5 uM incubated for 24 hrs by Annexin V and propidium iodide staining based FACS method2012European journal of medicinal chemistry, Nov, Volume: 57Synthesis and biological activities of polyquinoline derivatives: new Bcl-2 family protein modulators.
AID1377241Binding affinity to Galphao (unknown origin) assessed as change in melting temperature by differential scanning fluorimetry2017Journal of natural products, 07-28, Volume: 80, Issue:7
Natural Products Discovered in a High-Throughput Screen Identified as Inhibitors of RGS17 and as Cytostatic and Cytotoxic Agents for Lung and Prostate Cancer Cell Lines.
AID329555Induction of ERK2 phosphorylation2007Proceedings of the National Academy of Sciences of the United States of America, Oct-09, Volume: 104, Issue:41
Gambogic amide, a selective agonist for TrkA receptor that possesses robust neurotrophic activity, prevents neuronal cell death.
AID1304318Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 25923 assessed as zone of inhibition at 30 ug after 18 hrs by disk diffusion method2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Caged xanthones: Potent inhibitors of global predominant MRSA USA300.
AID1632364Antiproliferative activity against human PC3 cells assessed as growth inhibition by MTT assay2016Bioorganic & medicinal chemistry, 10-01, Volume: 24, Issue:19
Structure-activity relationship of Garcinia xanthones analogues: Potent Hsp90 inhibitors with cytotoxicity and antiangiogenesis activity.
AID648825Antiproliferative activity against human U251 cells after 24 hrs by MTT assay2012European journal of medicinal chemistry, May, Volume: 51Studies on gambogic acid (IV): Exploring structure-activity relationship with IκB kinase-beta (IKKβ).
AID1271462Induction of apoptosis in human T98G cells assessed as early-stage apoptotic cells at 400 nM after 24 hrs using annexin V/propidium iodide staining by FACS analysis2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
Gambogic acid induces apoptotic cell death in T98G glioma cells.
AID606792Inhibition of Hsp90 in human HeLa cells assessed as Her2 degradation at 0.01 to 20 uM after 36 hrs by Western blot analysis2011Journal of natural products, May-27, Volume: 74, Issue:5
Gambogic acid, a natural product inhibitor of Hsp90.
AID1456331Competitive inhibition of recombinant human PTP1B (1 to 322 residues) expressed in Escherichia coli assessed as substrate Km at 49.6 uM using pNPP as substrate by Lineweaver-Burk plot analysis (Rvb = 0.95 mM)
AID1593997Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Design, synthesis and antitumour and anti-angiogenesis evaluation of 22 moscatilin derivatives.
AID606864Inhibition of Hsp90 in human MCF7 cells assessed as Akt degradation after 36 hrs by Western blot analysis2011Journal of natural products, May-27, Volume: 74, Issue:5
Gambogic acid, a natural product inhibitor of Hsp90.
AID1271474Induction of apoptosis in human T98G cells assessed as increase of ROS level at 200 nM after 8 hrs using DCFH-DA staining by FACS analysis (Rvb = 2.4%)2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
Gambogic acid induces apoptotic cell death in T98G glioma cells.
AID1543858Cytotoxicity against patient derived inflammatory breast cancer cell spheroids assessed as increase in spheroid dissolution incubated for 24 hrs by propidium iodide/Acridine orange staining based dual-fluorescence viability assay2019European journal of medicinal chemistry, Apr-15, Volume: 168Synthesis, structure-activity relationship and in vitro pharmacodynamics of A-ring modified caged xanthones in a preclinical model of inflammatory breast cancer.
AID590500Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay2011European journal of medicinal chemistry, Apr, Volume: 46, Issue:4
Studies on chemical modification and biology of a natural product, gambogic acid (III): determination of the essential pharmacophore for biological activity.
AID648762Inhibition of TNF-alpha-induced IkappaBalpha degradation in human A549 cells at 4 to 8 uM treated 4 hrs before TNFalpha stimulation measured after 30 mins by Western blotting2012European journal of medicinal chemistry, May, Volume: 51Studies on gambogic acid (IV): Exploring structure-activity relationship with IκB kinase-beta (IKKβ).
AID1854081Antiproliferative activity against imatinib resistant human K562 cells assessed as cell growth inhibition measured after 48 to 72 hrs by MTS assay2022European journal of medicinal chemistry, Aug-05, Volume: 238The progress of small-molecules and degraders against BCR-ABL for the treatment of CML.
AID606795Inhibition of Hsp90 in human SKBR3 cells assessed as Her2 degradation after 36 hrs by Western blot analysis2011Journal of natural products, May-27, Volume: 74, Issue:5
Gambogic acid, a natural product inhibitor of Hsp90.
AID1557462Antiproliferative activity against human HL60 cells assessed as reduction in cell viability after 3 days by trypan blue dye based hemocytometer counting method2019Journal of natural products, 03-22, Volume: 82, Issue:3
Potential Anticancer Agents Characterized from Selected Tropical Plants.
AID606957Binding affinity to human full length Hsp90 expressed in insect Sf9 cells by SPR analysis2011Journal of natural products, May-27, Volume: 74, Issue:5
Gambogic acid, a natural product inhibitor of Hsp90.
AID1169353Cytotoxicity against human Raji cells2014Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22
Antimalarial activity of abietane ferruginol analogues possessing a phthalimide group.
AID1271476Induction of apoptosis in human T98G cells assessed as increase of ROS level at 200 to 400 nM after 10 hrs using DCFH-DA staining by fluorescence microscopic analysis2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
Gambogic acid induces apoptotic cell death in T98G glioma cells.
AID422519Cytotoxicity against human HeLa cells after 1 to 11 days by MTT assay2009Journal of natural products, Jan, Volume: 72, Issue:1
Cytotoxic polyprenylated xanthones from the resin of Garcinia hanburyi.
AID1456341Inhibition of recombinant human PTP1B (1 to 322 residues) expressed in Escherichia coli assessed as enzyme-inhibitor complex using pNPP as substrate preincubated for 60 mins followed by substrate addition measured at 30 secs interval for 10 mins by UV-spe
AID1594000Antiproliferative activity against human MKN45 cells incubated for 72 hrs by MTT assay2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Design, synthesis and antitumour and anti-angiogenesis evaluation of 22 moscatilin derivatives.
AID1456328Competitive inhibition of recombinant human PTP1B (1 to 322 residues) expressed in Escherichia coli assessed as substrate Vmax at 49.6 uM using pNPP as substrate by Lineweaver-Burk plot analysis (Rvb = 11.95 OD/min)
AID606790Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth after 72 hrs by cell titer 96 assay2011Journal of natural products, May-27, Volume: 74, Issue:5
Gambogic acid, a natural product inhibitor of Hsp90.
AID606944Inhibition of Cdc37 interaction with [35S]His-tagged HRI K199R mutant in reticulocyte lysate assessed as coadsorbed Cdc37 at 50 uM after 40 mins by SDS-PAGE and Western blot analysis2011Journal of natural products, May-27, Volume: 74, Issue:5
Gambogic acid, a natural product inhibitor of Hsp90.
AID590497Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay2011European journal of medicinal chemistry, Apr, Volume: 46, Issue:4
Studies on chemical modification and biology of a natural product, gambogic acid (III): determination of the essential pharmacophore for biological activity.
AID1304325Antibacterial activity against methicillin-resistant Staphylococcus aureus USA300 SF8300 assessed as growth inhibition after 18 to 20 hrs by microdilution assay2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Caged xanthones: Potent inhibitors of global predominant MRSA USA300.
AID1271467Induction of apoptosis in human T98G cells assessed as increase of Bax level at 200 to 400 nM after 10 to 24 hrs by Western blot analysis2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
Gambogic acid induces apoptotic cell death in T98G glioma cells.
AID1456335Reversible inhibition of recombinant human PTP1B (1 to 322 residues) expressed in Escherichia coli using pNPP as substrate incubated for 10 mins measured for 30 mins by spectrometric analysis
AID1207024Permeability of the compound at pH 7.4 by PAMPA2015Bioorganic & medicinal chemistry letters, Jun-15, Volume: 25, Issue:12
Novel natural-product-like caged xanthones with improved druglike properties and in vivo antitumor potency.
AID1271465Induction of apoptosis in human T98G cells assessed as increase of cleaved caspase-9 level at 200 to 400 nM after 10 to 24 hrs by Western blot analysis2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
Gambogic acid induces apoptotic cell death in T98G glioma cells.
AID736735Inhibition of MDM2-p53 interaction in human MCF7 cells assessed as reversal of MDM2-dependent inhibition of p53-induced transcriptional activity at 10 uM after 16 hrs by dual-luciferase reporter gene assay2013Journal of natural products, Apr-26, Volume: 76, Issue:4
Α-mangostin and gambogic acid as potential inhibitors of the p53-MDM2 interaction revealed by a yeast approach.
AID1169351Selectivity index, ratio of cytotoxic EC50 against human cells to EC50 for Plasmodium falciparum K12014Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22
Antimalarial activity of abietane ferruginol analogues possessing a phthalimide group.
AID1271479Induction of apoptosis in human T98G cells assessed as decrease in cell viability at 200 nM after 24 hrs using propidium iodide /Hoechst staining by FACS analysis in presence of NAC (Rvb = 2.9%)2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
Gambogic acid induces apoptotic cell death in T98G glioma cells.
AID1456323Inhibition of recombinant human PTP1B (1 to 322 residues) expressed in Escherichia coli using pNPP as substrate by Dixon plot analysis
AID606859Inhibition of Hsp90 in human SKBR3 cells assessed as induction of Hsp90 expression after 36 hrs by Western blot analysis2011Journal of natural products, May-27, Volume: 74, Issue:5
Gambogic acid, a natural product inhibitor of Hsp90.
AID648759Inhibition of NF-kappaB activation in human A549 cells assessed as inhibition of TNFalpha/IFNgamma/IL-1beta-induced NF-kappaB nuclear translocation treated 2 hrs before TNFalpha/IFNgamma/IL-1beta stimulation measured after 30 mins2012European journal of medicinal chemistry, May, Volume: 51Studies on gambogic acid (IV): Exploring structure-activity relationship with IκB kinase-beta (IKKβ).
AID1271463Induction of apoptosis in human T98G cells assessed as increase of cleaved caspase-3 level at 200 to 400 nM after 10 to 24 hrs by Western blot analysis2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
Gambogic acid induces apoptotic cell death in T98G glioma cells.
AID1593998Antiproliferative activity against human HepG2 cells incubated for 72 hrs by MTT assay2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Design, synthesis and antitumour and anti-angiogenesis evaluation of 22 moscatilin derivatives.
AID606995Binding affinity to human Hsp90 N-terminal domain (1 to 241) expressed in insect Sf9 cells by SPR analysis in presence of 20 uM geldanamycin2011Journal of natural products, May-27, Volume: 74, Issue:5
Gambogic acid, a natural product inhibitor of Hsp90.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (344)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (0.29)18.7374
1990's0 (0.00)18.2507
2000's68 (19.77)29.6817
2010's216 (62.79)24.3611
2020's59 (17.15)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 48.03

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index48.03 (24.57)
Research Supply Index5.86 (2.92)
Research Growth Index4.78 (4.65)
Search Engine Demand Index74.48 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (48.03)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.29%)5.53%
Reviews21 (6.03%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other326 (93.68%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]